Cysteine protease inhibitors as novel therapeutics for the prevention of primary graft dysfunction after lung transplantation by Rehm, Salome Raffaela Tosca Sofia
 
 
 
Dissertation der Fakultät für Biologie 
der Ludwig-Maximilians-Universität München 
 
 
Cysteine protease inhibitors as novel therapeutics for the 
prevention of primary graft dysfunction after lung 
transplantation 
 
 
 
 
 
Salome Raffaela Tosca Sofia Rehm 
aus 
München 
2019 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dissertation eingereicht am  08.08.2019 
1. Gutachter:    Prof. Dr. Elisabeth Weiß 
2. Gutachter:    PD. Dr. Joseph Mautner 
Mündliche Prüfung am  20.01.2020 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
„Nothing in life is to be feared, it is only to be understood.  
Now it’s the time to understand more, so that we fear less“ 
Marie Curie 
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Summary 
Lung transplantation (LTx) is lifesaving for patients with end-stage pulmonary diseases, 
when other therapeutic strategies have failed. Unfortunately, the mortality rate of 
patients on the LTx waiting list is quite high due to the low percentage of acceptable 
donor lungs. Additionally, LTx outcomes are harmed by the development of primary graft 
dysfunction (PGD) which is the leading cause for early mortality and morbidity. No 
effective treatment approach exists to date. Cysteine proteases play a substantial role in 
the complex biological pathways which are activated during cold storage and reperfusion 
of the transplant and thereby they contribute directly or indirectly to the early damage of 
lung transplants. In order to explore novel treatment options to prevent early lung 
transplant damage and dysfunction we used a clinical relevant murine model of 
orthotropic LTx to mimic the induction of ischemia reperfusion injury after extended 
graft storage in the cold. 
In the first project we developed a highly cell permeable, cysteine protease inhibitor, 
termed CysC-Alb, with increased circulatory half-life. This inhibitor was designed and 
produced to improve the storage condition of donor lungs adding CysC-Alb to the 
preservation solution during cold storage and ex vivo lung perfusion (EVLP), which could 
allow extended storage and better preservation. We found that ischemic storage times of 
lung transplants can be extended to 18 h with improved transplant function after 
transplantation when CysC-Alb is added to the preservation solution. Moreover, TNF-α 
release and apoptosis of lung cells were reduced after the preservation time in the CysC-
Alb group. Using an in vitro model of cold storage and simulated EVLP/Reperfusion, we 
recognized that not only the activity of cathepsin B (CatB), but also the activity of TNF-α 
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converting enzyme (TACE), one of the main TNF-α sheddases, are significantly lower after 
CysC-Alb treatment. This suggests that CatB is involved in the regulation of TACE either 
during maturation steps or on the cell surface. 
In the second project, we anticipated that patients on the LTx waiting list can be 
protected from neutrophil mediated inflammation and damage of the lung transplant 
after LTx through the preoperative treatment with a cathepsin C inhibitor (ICatC). 
Neutrophil serine proteases (NSPs) are main triggers of ischemia reperfusion injury after 
transplantation. The cysteine protease, cathepsin C acts as the key activator of NSPs 
during neutrophil maturation in the bone marrow. Pretreatment of recipient mice with 
ICatC significantly reduced serine protease activity in bone marrow neutrophils, 
diminished the inflammatory response and improved gas exchange after lung LTx 
compared to the control group. We conclude that the elimination of NSP activity by the 
pretreatment with ICatC reduces the early reperfusion-induced injury of transplanted 
lungs, which makes it a promising new therapeutic strategy to prevent PGD.  
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1. Introduction 
1.1 General introduction 
1.1.1 Lung transplantation 
Lung transplantation (LTx) is the final treatment option for patients suffering from end-
stage pulmonary disease, like chronic obstructive pulmonary disease (COPD, 32%), 
idiopathic pulmonary fibrosis (IPF, 24%) or cystic fibrosis (17%) (1). The total number of 
lung transplantations performed worldwide is approximately 4000 per year with a 
majority of bilateral transplantations and is still increasing every year. Despite significant 
improvements, the long-term outcome of LTx remains uncertain with a 5 year survival of 
53%, and for this reason has the worst short and long term prognosis amongst all organ 
transplantations (2). Development of primary graft dysfunction (PGD) is the leading cause 
of early morbidity and mortality after LTx, resulting in a one year survival of 
approximately 80 %. It is a consequence of ischemia reperfusion-injury, and occurs within 
the first 72 hours after reperfusion (3-5). 
1.1.2 Ischemia-reperfusion injury and primary graft dysfunction 
Ischemia is defined as a deficiency of oxygen caused by the restriction of the blood flow 
(6). During reperfusion, the blood supply returns to the ischemic tissue, which may 
induce and exacerbate tissue injury as a consequence of the absence of oxygen and 
nutrients during ischemia. This process is termed ischemia-reperfusion (I/R) injury, and is 
associated with increased permeability of capillaries, cell death programs, activation of 
the complement system, cytokine release and neutrophil recruitment (7-10). Moreover, 
it is identified as the key element of PGD, affecting an estimated 10 to 25 % of lung 
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transplants (6). Patients who survive after PGD have an impaired lung function and an 
increased chance of developing bronchiolitis obliterans syndrome (BOS), the 
manifestation of chronic lung rejection (11). 
 
Figure 1: Effect of primary graft dysfunction on the survival after LTx. Overall survival of 
LTx patients with and without PGD. Analysis time is years. The number at risk appears 
along the x-axis. The log-rank p-value for the comparison of PGD and no PGD is p < 0.001. 
From the American Thoracic Society (3). 
 
1.1.2.1 Cold ischemia 
One of the most common accepted methods utilized for the storage of organs prior to 
transplantation is hypothermic storage. Under this condition, the organ is kept at 
temperatures below physiological temperatures to suppress organ metabolism (12, 13). 
Lung transplants are generally considered acceptable for transplantation after static 
storage at 4°C for up to six hours. This method involves whole organ perfusion with the 
standard preservation solution, Perfadex. Although hypothermic storage protects the 
organ for some time, several events can occur, leading to the activation of inflammatory 
mediators that are highly deleterious to the organ during reperfusion. Briefly, during the 
course of cold storage (CS) metabolic rates of individual cells are slowed down, 
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intracellular ATP levels steadily decline, and ATPase dependent- transmembrane ion 
pumps show low activity. Consequently, intracellular and mitochondrial calcium levels 
increase, triggering cell swelling and cell death by necrotic, necroptotic, apoptotic, and 
autophagic mechanisms (14, 15).  This process is also associated with the formation of 
reactive oxygen species (ROS) and lipid peroxidation (16). Prolonged storage times are 
correlated with a higher risk of vascular damage and PGD. 
1.1.2.2 Consequences of reperfusion  
Although oxygen is restored after ischemia, reperfusion itself has detrimental 
consequences exacerbating tissue injury. It was first reported in the 1960s that the 
predicted beneficial effect of reperfusion is challenged by a paradoxical enhancement of 
the injury response following reperfusion of ischemic tissue (17). The mechanism 
underlying reperfusion injury is complex and involves upregulation of adhesion 
molecules (e.g. intergrins) on the cell surface, release of pro-inflammatory cytokines and 
leukocyte activation. Pulmonary intravascular non-classical monocytes (passenger 
monocytes) from the donor (early phase of reperfusion) and macrophages that are 
carried to the lung with the newly restored blood flow (later phase of reperfusion) 
release inflammatory cytokines, which are pivotal for the further recruitment of recipient 
neutrophils and leukocytes into the lung. Activated neutrophils locally secret a wide 
range of pro-inflammatory mediators, ROS and proteolytic enzymes (18-20), irreversibly 
damaging lung tissue. Clear evidence of the involvement of neutrophils has been 
revealed in preclinical and clinical studies in which neutrophil depletion was protective 
against I/R injury (21-23). In a more recent approach, neutrophil influx was attenuated, 
when non-classical monocytes were depleted in murine donor lung transplants (24). 
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Thus, neutrophils play a major role in I/R injury after reperfusion, representing a 
potentially important therapeutic target for reducing PGD. 
1.1.3 Ex vivo lung perfusion  
Donor lung shortage has been the main reason for the increasing mortality of patients on 
the waiting list. Donor lungs are often rejected for transplantation since they are exposed 
to various stress and injury before and during brain death such as thoracic trauma, 
ventilator-associated pneumonia and barotrauma. Nevertheless, about 40% of these 
lungs can be considered appropriate for transplantation (25). In the last decade, ex vivo 
lung perfusion (EVLP) was shown to safely increase the donor lung pool. During EVLP, 
donor lungs are ventilated and held at body temperature (37 °C), which keeps the lungs 
viable and metabolic active. During this time period, lungs can be examined, reassessed 
and reconditioned by treatment in the normothermic state (26). The results from the 
first prospective clinical trial in 2011 have shown that EVLP is able to reconstitute donor 
lungs with inferior quality so that the LTx outcome (PGD development) is similar to 
standard criteria donor lungs (27). To date, three different protocols for the EVLP 
procedure exist, with the Toronto protocol being the most commonly used protocol. In 
principle, the lung undergoes a cold perfusion before it is harvested and is transported to 
the recipient hospital in static cold storage on ice. The lung is then connected to the ex 
vivo device and assessed.  
1.1.4 Cysteine proteases 
Proteases are peptide bond-cleaving enzymes. This large family of proteolytic enzymes 
can be further grouped according to 1) the position of the cleavage site in the 
polypeptide chain of the substrate (exopeptidases and endopeptidases), 2) which 
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terminus of the substrate is involved in the cleavage (aminopeptidase and 
carboxypeptidase), and 3) according to the active site region residues (aspartate, 
metallo, serine, cysteine proteases). Cysteine proteases are either exo- or 
endopeptidases, which use the cysteine residue in the active site for hydrolysis. 
1.1.4.1 Structure and occurrence of cysteine proteases  
Cysteine proteases are distributed among most of the living organisms, from bacteria and 
viruses to fungi and mammals (28). The most intensively investigated and largest family 
of cysteine proteases is the superfamily of papain-like cysteine proteases, which 
comprise calpains and lysosomal cathepsins in mammels (29). Lysosomal cathepsins 
share a high sequence similarity with papain, a plant protease isolated from a papaya, 
which is the prototype for all cysteine proteases. The highest sequence similarity of all 
cathespins is found in active site which is formed by cysteine (Cys-25), histidine (His-159) 
and asparagine (Asn-157) residues. All cathespins are synthesized as inactive precursor 
enzymes with a 15-21 residue long signal peptide, a propeptide domain consisting 41 and 
251 amino acid residues, and a mature domain of 214 to 260 amino acids. The 
propeptide domain prevents premature proteolysis until it is cleaved by other enzymes 
or self-processing (30). In addition, lysosomal cathepsins possess putative N‐linked 
mannose‐6‐phosphate glycosylation sites that are used to target proteases into 
lysosomes. For many years these enzymes were believed to have redundant “house-
keeping functions” and as such have not been considered to have any value as drug 
target. However, over the past decades large progress was made in identifying new 
members and understanding the physiological roles of cathepsins. It has become clear 
that cathepsins have a multi-faceted role in several physiological processes including 
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extracellular matrix remodeling, antigen presentation and processing events (31). As 
such they are also involved in many pathological conditions and represent promising 
drug targets for cancer (32), arthritis, osteoporosis (33), Alzheimer’s disease and a variety 
of parasitic infections (34) . 
1.1.4.2 Protease nomenclature 
The specificity of proteases is determined by the amino acid sequence of substrates 
cleaved by the protease. To guarantee successful substrate cleavage, a close interaction 
between the substrate sequence that is cleaved (scissile bond) and the active site cleft of 
the protease is necessary. Schechter and Berger introduced a nomenclature to describe 
the interaction of a protease and its substrate (35). All protease subsites and substrate 
residues are numbered and named with regard to the location of the scissile bond. 
Consequently, the N-terminal substrate residues of the scissile bond are referred to as 
P3,P2,P1 etc. and the residues on the C-terminal side P1’, P2’,P3’ etc. Accordingly, the 
protease subsites that interact with the substrate residues are called S3, S2, S1 etc. on 
the N-terminal side and S1’, S2’, S3’ etc. on the C-terminal side. The scissile bond is 
located between P1 and P1’ as indicated in Figure 2. 
 
Figure 2: Schechter and Berger nomenclature. Protease subsites are designed as S1, S2, 
S3, S1’, S2’ and S3’ and the amino acid residues of the substrate are named P1, P2, 
P3,P1’, P2’ and P3’ respectively. Cleavage of the substrate occurs at the scissile bond 
between P1 and P1’. 
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1.1.4.3 Cysteine protease hydrolysis 
Cysteine proteases catalyze peptide bond hydrolysis through nucleophilic reaction of the 
cysteine thiol with the substrate carbon carbonyl. The first step of the reaction involves 
formation of a non-covalent enzyme-substrate complex. Once this complex is formed 
and stabilized with hydrogen bonds, the negative charged SH group of the cysteine thiol 
enables a nucleophilic attack on the scissile bond of the substrate carbonyl carbon, 
producing the first tetrahedral intermediate. This intermediate is generally stabilized by 
hydrogen bonding through the interaction with the oxyanion hole in the active site. 
Acylation of the enzyme occurs through the protonation of the amine group under the 
release of the first product.  This step is followed by the hydrolysis of the acyl-enzyme 
complex of the carbon carbonyl by a water molecule (deacylation), forming the second 
tetrahedral intermediate, which finally dissociates into the cleaved substrate and the 
active enzyme (Figure 3). 
1. Introduction 
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Figure 3: Mechanism of hydrolysis by cysteine proteases. The thiol group of the cysteine 
protease attacks the carbon carbonyl of the substrate and forms the tetrahedral 
intermediate which resolves in an acyl-enzyme complex with the release of the first 
product. The active enzyme is then regenerated through the nucleophilic attack of a 
water molecule (30). 
 
1.1.4.4 Inhibitors of cysteine proteases 
For many types of proteases, activity is regulated by the balance of the amounts of active 
proteases and inhibitors. Active site directed inhibitors can be divided into covalent/non-
covalent and reversible/irreversible inhibitors. Irreversible inhibition always includes 
covalent binding of the inhibitor; whereas reversible inhibition mostly involves non-
covalent binding, but not in all cases. The most abundant family of endogenous cysteine 
protease inhibitors are cystatins: the intracellular cystatin A and B are commonly called 
stefin A and B; the circulating kininogens; and the extracellular cystatin C (36, 37). All of 
them are low molecular weight peptide inhibitors, which bind tight and almost 
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irreversibly by interacting on multiple sites with the active cysteine protease. Synthetic 
cysteine protease inhibitors can be either low or high molecular weight inhibitors and 
typically display common structural similarities. They include an at least two amino-acid 
peptide sequence to achieve high protease affinity and substitutable electrophilic groups 
to irreversibly react with the cysteine residue of the active site. Many different synthetic 
inhibitors have been developed, which can be classified into peptidyl nitriles and 
aldehydes, epoxides, aziridines and many more (28). 
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1.2 CysC-Alb in LTx – Introduction 
1.2.1 Albumin  
Alb is the most abundant plasma protein in the body with a size of 67 kDa (41). It consists 
of three homologous domains, which function together to give Alb its unique binding 
properties. Hence, Alb transports a lot of endogenous and exogenous compounds, such 
as fatty acids, steroids and ions. Additionally, it is responsible for the stabilization of the 
colloidal osmotic pressure and plays a major role in pH buffering of serum (42). It is 
predominately synthesized by hepatocytes in the liver, from which it is continuously 
secreted, and degraded at a rate of 14 g per day (43). The circulatory half-life of Alb is 21 
days in humans (mice), and is strongly dependent on the interaction with the cellular 
expressed neonatal Fc receptor (FcRn). The FcRn-mediated recycling mechanism protects 
Alb from lysosomal degradation and thereby increases its serum half-life. This feature is 
unique for Alb and IgG, which both bind to distinct and non-interactive binding sites of 
FcRn in a strictly pH-dependent manner, with binding at acidic pH (pH 6) and release or 
no binding at neutral pH (7,4) (44). The FcRn is a heterotrimeric receptor, comprising of a 
major histocompatibility class I (MHC-I) heavy α-chain and a non-covalent associated β-
microglobulin light chain (45). It was shown, that domain III of Alb is required for binding 
to the neonatal Fc receptor (FcRn), as well as three conserved histidine residues (H464, 
H510 and H535), which become positively charged at acidic pH (46). 
1.2.2 FcRn-mediated recycling pathway 
The pH dependence of the interaction is crucial for the FcRn-mediated rescue of its 
ligands from lysosomal degradation. Initially, extracellular Alb is pinocytosed at neutral 
    1. Introduction 
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pH. Upon acidification of the early endosome Alb binds to the FcRn membrane protein, 
which results into the recycling of Alb back to the cell surface where FcRn-bound Alb is 
exposed due to neutral pH of the plasma. In contrast, non FcRn-bound proteins are 
sorted to late endosomes and subsequently to lysosomes where they are degraded (44, 
47, 48). The FcRn-mediated recycling mechanism exists in almost all cell-types. 
 
 
Figure 4: The FcRn-mediated recycling mechanism. Schematic representation for FcRn-
mediated albumin recycling using an endothelial cell as example. Upon pinocytosis, 
albumin binds to membrane-bound FcRn at the slightly acidic pH (~ pH 6) of the 
endosome. Other non FcRn-bound proteins are sorted to lysosomes for degradation. The 
FcRn-albumin complex is either recycled back to the apical membrane (exocytosis) or 
from the apical to the basolateral membrane (transcytosis), where albumin is released 
due to the weak affinity to FcRn at neutral pH (pH 7.6).  
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1.2.3 Albumin therapeutics 
The therapeutic efficiency of small drug molecules, especially biopharmaceuticals is 
hampered by their short half-life as they are rapidly cleared by the kidney or liver due to 
their low molecular mass. Consequently, strategies to extend serum half-life of 
pharmaceuticals have been extensively explored. Attachment of pharmaceuticals to Alb 
to increase their size in order to prevent kidney clearance and using its FcRn-mediated 
recycling mechanism has been shown to be a promising purpose. Various molecules have 
been joined to Alb either non-covalently or covalently by conjugation or genetic fusion 
primarily to treat diabetes, cancer, rheumatic arthritis and infectious disease (49-53). 
Beside its unique recycling mechanism, there are several other advantages of Alb as a 
drug carrier: 1) as an endogenous protein it is native to the body; 2) it is stable over a 
wide pH range, therefore unaltered by denaturating agents and solvents at moderate 
concentrations (41); 3) it is readily available as it is the most abundant plasma protein. 
1.2.4 Cystatin C – endogenous inhibitor of cysteine proteases 
Cystatin C (CysC) is a member of the cystatin superfamily of cysteine protease inhibitors. 
It is considered to be the physiologically most important endogenous inhibitor of 
cysteine cathepsins from the papain family, such as CatB, CatL, CatS and CatH, as well as 
the asparaginyl endopeptidase legumain (54). Physiologically, the role of CysC is the 
protection of the organism from extracellular proteases released or leaked from 
lysosomes e.g. from damaged or tumor cells. CysC is a single-domain protein with a signal 
peptide, hence being secreted and therefore be found extracellular. It is expressed in all 
nucleated cells and secreted at a constant rate. Due to its small size of 13 kDa and basic 
pI (~9.0), it is quickly filtered by the glomerulus (55). The interaction of CysC and chicken 
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papain as an example for CysC-protease inhibition has been intensively investigated. 
Three regions of the CysC 122-amino acid polypeptide chain have been implicated in the 
formation of the reversible enzyme-inhibitor complex. The most critical region for the 
tight enzyme-binding property of CysC is the N-terminal tri-peptide sequence L9-V10-G11 
which interacts with the cysteine protease pockets S3 S2 S1 respectively. Hereby, it was 
shown that L9 is the discriminating residue for binding to CatS, CatB and CatL. Together 
with the two other regions, the evolutionary conserved Q55-I-V-A-G59 and the C-terminal 
P105-W
106, they form a wedge-shaped structure occluding the protease substrate-binding 
sites, thus inhibiting them (56). 
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1.3 CatC inhibition in LTx – Introduction 
1.3.1 Neutrophil granulocytes 
Neutrophil granulocytes are derived from myeloid cells and account for 40-70% of 
circulating leukocytes in the blood. They are named according to their high content of 
dense packed granules in the cytoplasm. One of their unique characteristics is the 
segmented nucleus, for which they are also called polymorphonuclear cells (PMNs). 
Neutrophil granulocytes, in the following just called neutrophils are among the first cells 
to be recruited to sites of inflammation. Neutrophils reach the inflammatory site via the 
blood and transmigrate through the endothelial wall into the tissue via a multistep 
process, which involves rolling, adhesion, firm attachment and diapedesis (97). The 
primary function of neutrophils at the inflammatory site is host defense with the help of 
their antimicrobial cocktail that includes oxidants, proteases and cationic peptides. These 
microbial compounds are stored in three different classes of granules: primary 
(azurophilic), secondary (specific) and tertiary (gelatinase) granules. They are formed 
sequentially during different stages of granulocyte development in the BM and therefore 
differ in their contents (98).  
Pathogens are phagocytosed by neutrophils and the resulting phagosomes fuse with 
neutrophil cytoplasmatic granules to form phagolysosomes. Engulfed pathogens can be 
destroyed in several ways, e.g. by the production of ROS, antimicrobial proteins from the 
lysosomes or proteases like neutrophil serine proteases (NSPs) (99). Furthermore, 
neutrophil activation can lead to the formation of extracellular traps (NETs), a network of 
extracellular DNA fibers, which are decorated with antimicrobial enzymes and peptides in 
order to kill pathogens (100). Under pathological conditions, antimicrobial compounds 
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are released in an uncontrolled way into the extracellular space where they paradoxically 
can damage host tissue. 
1.3.2 Neutrophil serine proteases 
The NSPs, neutrophil elastase (NE), cathepsin G (CatG), proteinase 3 (PR3) and the 
recently discovered neutrophil serine protease 4 (NSP4) belong to the 
trypsin/chymotrypsin proteases and are stored in azurophilic granules. They acquire 
catalytic activity at the neutral pH of phagolysosomes (101, 102). The genes for NE (ELA2, 
ELANE) and PR3 (PRTN3) and NSP4  form a tight linked cluster on chromosome 19 in 
humans and on chromosome 10 in mice. By contrast, the gene encoding CatG is located 
within a separate cluster on syntenic regions of human and mouse chromosome 14, 
containing also the genes for chymase, granzyme H and granzyme B (103). All human 
and mouse NSPs contain an active center with the catalytic triad His57, Asp102 and Ser195 
(104). Besides their proteolytic properties, evidence indicates that NSPs play an 
important role in inflammation (102, 105). 
1.3.3 Serine protease biosynthesis 
NSPs are synthesized as inactive precursor (zymogens) during the promyelocytic stage of 
neutrophils in the BM. After cleavage of the two N-terminal amino-residues by 
dipeptidypeptidase I (DPPI) also known as cathepsin C (CatC), NSPs are in their 
enzymatically active conformation (106-108). The now accessible Ile16 is able to interact 
with Asp194, which results in a conformational change unveiling the active site. Mature 
NSPs are stored in azurophilic granuels of neutrophils until their regulated secretion in 
response to several stimuli. 
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Figure 5: Neutrophil serine protease maturation. CatC plays a key role in the activation 
of the NSPs, CatG, PR3 and NE in the BM. Active NSPs are stored in azurophile granules in 
neutrophils. Adapted from (109).  
 
1.3.4 Pathophysiological function of NSPs 
NSPs are important modulators of the innate immunity; however, uncontrolled 
neutrophil activation and subsequent NSP release participate in the pathogenesis of 
inflammatory diseases. Examples are autoimmune disorders and chronic inflammatory 
diseases like granolumatosis with polyangiitis, lupus nephritis, cystic fibrosis and lung 
emphysema (110, 111). The disruption of the balance between proteases and their 
inhibitors is a major feature of these diseases. Hence, a tight regulation of NSP activity is 
necessary to maintain a healthy homeostasis. Under physiological conditions, NE and PR3 
activities are antagonized by AAT, elafin, monocyte neutrophil elastase inhibitor, 
secretory leucocyte protease inhibitor and α2-macroglobulin. CG is inactivated by 
monocyte neutrophil elastase inhibitor, secretory leucocyte protease inhibitor, AAT and 
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additionally anti-chymotrypsin (112). Based on their highly important role in 
inflammatory processes, NSPs represent an attractive therapeutic target. 
1.3.5 Role of neutrophils in I/R injury 
Neutrophils are known to play a major role in the development of I/R injury after organ 
transplantation. During reperfusion, neutrophils are the primary effector cells recruited 
to the allograft by the neutrophil chemoattractants IL-8 and CXCL2 (113, 114). Upon 
arrival in the tissue, neutrophils secret toxic free radicals and NSPs that can irreversible 
damage the transplant tissue and therefore also impair tissue function. In several 
preclinical and clinical studies it was demonstrated that neutrophil depletion was 
protective against tissue damage after organ transplantation (21-23). Pharmacological 
targeting of NE strongly reduced inflammatory processes in a series of experimental and 
clinical settings, and NE inhibitors are considered for various therapeutic applications 
(115-118). However, the mechanisms of NSP function in this process are poorly 
understood. So far, it is known that NE promotes epithelial and endothelial permeability 
by alteration of the actin skeleton and by proteolytic cleavage of E-cadherin and 
endothelial VE-cadherin (119, 120). NSPs may also act through binding to cell surface 
receptors thereby inducing signal transduction pathways of inflammation and apoptosis 
in the lung (121-123). Nevertheless, through the broad spectrum of NSP actions and 
substrates it is hard to define their downstream mechanisms involved in the 
development and progression of I/R injury. 
1.3.6 CatC – a therapeutic target 
The cysteine protease, CatC, also known as dipeptidypeptidase I (DPPI) belongs to the 
papain superfamily and acts as an N-terminal exopeptidase. As mentioned above, a key 
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function of CatC is the activation of NSP zymogens through the removal of their pro-
peptide sequences. Homozygous loss of CatC function mutations in humans are the 
genetic cause of the rare Papillon-Lefevre syndrome (PLS, OMIM: 245000) primarily 
occurring in consanguineous families. The symptoms are quit variable, but not life-
threatening (124, 125). Over the last years, CatC came into focus of attention as a 
therapeutic target for various NSP-driven inflammatory diseases. It was first shown in 
non-human primates that pharmacological inhibition of CatC results in the elimination of 
NSPs protein levels and activity in peripheral blood and BAL neutrophils attracted to the 
lung by intratracheal lipopolysaccheride (LPS) instillation (126). Two different small 
molecule CatC inhibitors (AZD7986 and GSK2793660) have been evaluated in a phase 1 
clinical trials with healthy humans. One drug candidate (AZD7986) successfully reduced 
NE activity in human blood neutrophils in an dosage-dependent manner, while the other 
one only inhibited CatC activity, but not the downstream activities from NSPs (127, 128). 
Further therapeutic trials will be undertaken on the basis of these positive safety results. 
1.3.7 ICatC – a potent nitrile CatC inhibitor 
Several potent and selective CatC inhibitors have been described in literature (129, 130). 
However, most of them are associated with poor metabolic stability based on their 
peptidic and electrophilic nature, as well as cytotoxicity. In the last years dipeptidyl 
nitriles have emerged due to their strong inhibitory activity against human CatC, which 
show no cytotoxic effects and effectively block downstream elastase-like NSPs (131, 132). 
The warhead in cyclonitrile inhibitors targeting CatC is the nitrile group that binds 
covalently to the nucleophilic cysteine residue of the active site (133). The reversible 
cyclonitrile CatC inhibitor available to us ((S)-2-amino-N-((1S,2S)-1-cyano-2-(4’-(4-
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methylpiperazin-1-ylsulfonyl)biphenyl-4-yl)cyclopropyl) butanamide) was first described 
as XPZ-01 by Unizyme Laboratories (134) and will hereinafter be referred to as ICatC. It 
was identified as a potent inhibitor of human and rodent CatC and was successfully used 
to reduce BM NSP activity which resulted in anti-arthritic activity in a mouse model of 
rheumatoid arthritis (134). The inhibitor (ICatC) used in this study was available to us for 
our mouse LTx study. 
 
Figure 6: Chemical structure of ICatC. ICatC, (S)-2-amino-N-((1R,2R)-1-cyano-2-(4’-(4-
methylpiperazin-1-ylsulfonyl)biphenyl-4-yl)cyclopropyl)butanamide was synthesized by 
Brice Korkmaz, Tour, France. The inhibitory potency and selectivity were determined on 
recombinant human CatC. IC50 = 0.015 ± 0.001. 
 
 
1.4 Objectives of this dissertation 
LTx faces two major challenges; the first one is the ischemic storage of the donor organ, 
during which the blood and oxygen supply is disrupted. The second challenge is 
reperfusion, when the blood flow is restored back to the ischemic tissue. Both contribute 
to PGD, which has been associated with acute and chronic lung rejection. To date, no 
effective treatment approach exists. Therefore the objective of this dissertation was to 
develop new treatment options in order to prevent the immediate inflammatory 
response in the recipient lung after LTx and to increase the donor organ pool suitable for 
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transplantation. Using cysteine protease inhibitors, two different approaches were 
chosen: 
The first pre-clinical study was conducted to reduce early tissue damage which is caused 
by lysosomal leakiness, cell death and lysosomal cathepsin release into the extracellular 
space during CS and EVLP. We hypothesized that cathepsins can be neutralized with a 
cysteine protease inhibitor added to the preservation solution and thereby protect lung 
cells and preserve lung function by preventing tissue-damage during cold graft storage 
and reperfusion. We further intended to increase the donor organ pool by allowing 
longer storage times. The endogenous inhibitor, CysC, has been shown to effectively 
reduce the cysteine protease pool, more specifically cathepsin S, B and L (CatS, CatB, 
CatL).  Unfortunately the direct use of this natural low-molecular mass inhibitor has been 
harmed by a short half-life period and poor accessibility of the recombinant product to 
diseased areas. Hence, new fusion proteins consisting of Alb and CysC were developed by 
us to create more effective inhibitors. For proof of concept experiments, a clinical 
relevant lung preservation protocol was set up, including extended CS and EVLP. 
Perfadex was supplemented with CysC-Alb (0.4 µg/ml) for extended CS (18h) and EVLP at 
37°C (2h) prior to  the usage of a murine orthotropic LTx model (Figure 6 established by 
(39)). Using this model the anticipated enhancement of the lung function and the 
protection of lung cells after adding Cysc-Alb to Perfadex was investigated. To assess 
possible mechanisms of lysosomal cathepsin mediated tissue damage after CS and EVLP 
more in detail, an in vitro model of cold ischemia and simulated EVLP/Reperfusion was 
developed. 
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In the second part of this dissertation, we considered the use of CatC inhibitors for the 
pre-operative treatment of patients on the waiting list for LTx surgery. The aim of this 
preclinical study was to examine if the immediate inflammatory response triggered by 
NSPs after reperfusion can be prevented by the pre-treatment of recipient mice with a 
CatC inhibitor. In detail, we investigated whether NSP maturation in the BM could be 
blocked by a CatC inhibitor and determined the effect on lung graft function and quality 
after LTx. 
To initiate proof of concept experiments, we used the murine orthotopic LTx model 
which was used in our previous study. Recipient mice were treated with a CatC inhibitor, 
ICatC, twice daily for 10 days prior to LTx. We used a reversible cyclonitrile CatC inhibitor 
ICatC, which was first described as XPZ-01 by Unizyme Laboratories. 
 
Figure 7 Mouse model of orthotropic lung transplantation. (A) Model of a murine lung: 
the right lung consists of four lobes and the left lung only of one lobe. (B) Principle of left 
LTx in the mouse: first the pulmonary artery (PA, red) is attached to the recipient, then 
the pulmonary vein (PV, blue), and finally the bronchus (Br, orange). (C) Picture of left 
donor lung attached to the recipient during surgery (taken by Natalia Smirnova). 
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2. Materials and methods 
2.1 List of materials 
2.1.1 Chemicals and Consumables 
Chemicals were purchased from the companies BD Biosciences (Franklin Lakes, NJ, USA), 
Bio-Rad Laboratories (Hercules, CA, USA), Biozym (Hessisch Oldendorf, Germany), Life 
Technologies (Carlsbad, CA, USA), Merck (Darmstadt, Germany), PAA Laboratories GmbH 
(Pasching, Austria), GE Healthcare (Little Chalfont, Buckinghamshire, UK), Qiagen (Hilden, 
Deutschland), Roth (Karlsruhe, Germany), and Sigma-Aldrich (St Louis, MO, USA), unless 
mentioned otherwise. Restriction enzymes and T4 deoxyribonucleic acid (DNA) ligase 
were purchased from New England Biolabs (Ipswich, MA, USA) and Thermo Fisher 
Scientific (Waltham, MA, USA). Consumables such as pipette tips, centrifuge tubes, 
reaction tubes, and microwell plates were procured from Biozym (Hessisch Oldendorf, 
Germany), Eppendorf (Hamburg, Germany), BD Biosciences and Nunc/Thermo Fisher 
Scientific (Waltham, MA, USA). Cell culture flasks and dishes were obtained from Corning 
(Corning, NY, USA) and BD Biosciences. 
2.1.2 Laboratory equipment 
  Device designation Supplier 
Autoclave Varioklav, H+P Labortechnik, 
Oberschleissheim, Germany 
Axio Imager. Z1 Carl Zeiss, Göttingen, Germany 
Balances PM 4800 Delta Range, Mettler-Toledo, 
Columbus, OH, USA 2001 MP2, Sartorius, 
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Göttingen, Deutschland 
Centrifuge 5417R, Eppendorf 
5417C, Eppendorf 
Rotanta 460R, Hettich, Tuttlingen, 
Germany 
Detection sytem Chemidoc Biorad, Munich, Germany 
Gel electrophoresis chambers/ power 
supplies 
Bio-Rad, Amersham-Pharmacia, MPI 
workshop 
Incubation shaker HT Multitron, Infors, Bottmingen, 
Switzerland 
Incubator BBD6220, Heraeus, Thermo Scientific, 
Waltham, USA 
Icemachine Ziegra, Isernhagen, Germany 
Magnetic stirrer MR3003, Heidolph, Kelheim, Germany 
Microplate reader FLUOStar Optima, BMG Labtech, 
Offenburg, Germany 
Microscope Leica DM IL, Leica Microsystems, Wetzlar, 
Germany 
NanoDrop 2000c Peqlab Biotechnology GmbH, Erlangen, 
Germany 
pH-meter Inolab pH Level 1, WTW, Weilheim, 
Germany 
PCR cycler T3 Thermocycler, Biometra, Göttingen, 
Germany 
Semidry blotter Biometra, Göttingen, Germany 
Shaker 130 basic, IKA KS 
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Spectrophotometer ND-1000, peqlab, Erlangen, Germany 
Thermoblock Thermoblock 
Water bath incubator  MA6, Lauda, Lauda-Königshofen, Germany 
Water preparation Milli Q Advantage, Millipore, Billerica, MA, 
USA 
 
2.1.3 Oligonucleotides 
Oligonucleotides were synthesized by Eurofins Genomics (Ebersberg, Germany).  
Name Sequence Application 
DJ3710 5’-CGGGGTACCAGGTTCCACcGGTGAAGCACACAAGAGTGA-3’ cloning 
DJ3729 5’-GATGTCCGGAGGCTAACGCGTCTTTGCATCTAGTGACAAG-3’ cloning 
DJ3765 5’-TGGGTACCTGGCTCAACCGGACCTAGGATGCTGGGGGCT-3’ cloning 
DJ3766 5’-GACTCTTGGTGCACGTGGT-3’ cloning 
DJ3767 5’-TGGGTACCTGGCTCAACCGGACTGCTGGGGGCTCCCGAGGA-
3’ 
cloning 
TNFa-2f 5’-CACCACGCTCTTCTGTCT-3’ real-time PCR 
TNFa-2r 5’-GGCTACAGGCTTACTC-3’ real-time PCR 
IL-10-1f 5’-TCTGTCTAGGTCCTGGAGTC-3’ real-time PCR 
IL-10-1r 5’-GGAGCAGGTGAAGAGTGA-3’ real-time PCR 
IL-1α-1f 5’-AGCGTCCAAGGAGAAGAC-3’ real-time PCR 
IL-1α-1r 5’-CTGTCATAGAGGGCAGTCC-3’ real-time PCR 
IL-1βf 5’-CAACAAACAAGTATTCTCCATG-3’ real-time PCR 
IL-1βr 5’-GATCCACACTCTCCAGCTGCA-3’ real-time PCR 
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2.1.4 Plasmids 
Plasmid Origin 
pTT5 NRC Biotechnology Research Institute, 
Ottawa, USA 
pTT5_MIP-2(5-73)_RUBY_H6 Therese Dau, AG Jenne 
pTT5_Ruby_Alb_CysC Salome Rehm, AG Jenne 
pTT5_Ruby_CysC Salome Rehm, AG Jenne 
pTT5_Alb_CysC Salome Rehm, AG Jenne 
 
Vector maps can be found in the Appendix 7.1. 
2.1.5 E.coli bacterial strains 
Strain Genotype Provider 
DH5α F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 
endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 
gyrA96 relA1 
18265017, Thermo Fisher 
Scientific 
 
2.1.6 Recombinant and purified proteins 
Protein Origin 
CystatinC-albumin Salome Rehm, Jenne Lab 
CystatinC-albumin-ruby Salome Rehm, Jenne Lab 
CystatinC-ruby Salome Rehm, Jenne Lab 
Cystatin C  R&D systems 
Cathepsin B R&D systems 
2. Materials and methods 
28 
 
Cathespin S R&D systems 
 
2.1.7 Antibodies 
Primary antibodies 
Antigen Species Klone Provider Catalog No. 
Mouse PR3 Goat  AG Jenne  
Mouse NE Rabbit  Abcam ab68672 
Mouse AAT Rat RM0527-3E39 Abcam ab205152 
Ly-6G Rat 1A8 Biolegend 127602 
Cystatin C Rabbit EPR4413 Abcam ab109508 
 
Secondary antibodies 
Antigen Species Label Provider Catalog No. 
Goat mouse HRP Merck Millipore AP186P 
Rabbit goat HRP Merck Millipore 12-348 
Rat IgG+IgM goat HRP Jackson 
Immuno 
Research 
112-035-068 
 
Other 
Antigen Label Provider Catalog No. 
Avidin Peroxidase Invitrogen  434423 
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2.1.8 Förster/Fluorescence resonance energy transfer (FRET) substrates 
Sequence Cleaving proteases Provider 
TAMRA-GVRRVVQVQD-Dap 
(CF) 
Mouse PR3 KH Wiesmüller, EMC 
Microcollection 
Abz-GAVVASELR-Y-(NO2)-D Mouse NE, mPR3 KH Wiesmüller, EMC 
Microcollection 
Z-Arg-Arg-AMC Human Cathepsin B Bachem, 404789 
Z-Val-Val-Arg-AMC Human Cathespin S Bachem, 4016422 
 
2.2 Molecular biological methods 
2.2.1 Polymerase chain reaction (PCR) 
PCR is a fast and easy method to amplify a specific DNA fragment from a larger DNA 
template. Two oligonucleotides, so called primers are required to flank the two ends of 
the DNA fragments. They contain a free 3´-OH at one end, ensuring the synthesis of the 
new strand in only one direction. The synthesis is carried out by a polymerase by adding 
and linking new nucleotides to the primers, thereby generating many copies of the 
amplicon. A typical PCR cycle consists of denaturation of the DNA double helix, annealing 
of the primers to the single strands and a final extension step in which the DNA 
polymerase extends the DNA fragments to their full length. The Phusion High Fidelity 
polymerase from Finnzymes (New England Biolabs) was used for all PCRs. The conditions 
used are described in the tables below. 
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Phusion PCR reaction (25 μl):  
 
Component     Volume (µl) 
template DNA     2-5ng 
Phusion HF buffer    1x 
dNTPs       200 µM 
forward primer (10 µM)   0.5 µM 
reverse primer (10 µM)   0.5 µM 
Phusion DNA polymerase   0.2 µl 
dH2O      up to 25 µl 
     
 
Phusion PCR program:  
Step  Temperatures  Periods Cycles 
1  95°C   30 s     
2  98°C   10s  
3  60°C   30s  x25 
4  72°C   60 s  
5  72°C   10 min 
 
 
2.2.2 Restriction enzyme digest  
Restriction endonucleases are enzymes which cleave DNA at a specific recognition 
sequence. The DNA obtained from PCR was digested with one or two different restriction 
enzymes to produce linear fragments with non-complementary ends. One unit is defined 
as the amount of restriction enzyme needed to digest 1 µg of DNA in one hour at room 
temperature. The protocol was performed according to the manufacturers’ instructions. 
Restriction enzymes were purchased from New England Biolabs. 
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2.2.3 Agarose gel electrophoresis 
Due to their negatively charged sugar-phosphate backbone, DNA fragments can be 
separated in an agarose gel matrix in an electric field according to their size. Agarose gels 
were prepared with TAE buffer supplemented with SYBR Safe (Life Technologies, dilution 
1: 10000 ) to visualize DNA by exposure to UV light (254-366 nm).  Depending on the size 
of the DNA fragment, the percentage of the agarose in the gels ranged from 0.5 – 2 % 
(w/v). 
DNA samples were mixed with 1x loading buffer and electrophoresis was performed with 
a constant voltage of 60 volt (small chambers) for 1 hour. As a molecular marker Gene 
Ruler DNA ladder (1kb, Fermentas, Thermo Fisher Scientific) was used. The fluorescence 
signal was detected with a Chemidoc imaging system (Bio-Rad). 
Buffer/Solution Composition 
50 x TAE buffer 243 g Tris 
100 ml 0.5 m EDTA pH 8.0 
57.1 ml acetic acid 
up to 1 l dH2O                
10 x DNA loading dye 0.25% (w/v) bromphenol blue 
0.25% (w/v) xylenecyanol 
50% (w/v) glycerol 
 
2.2.4 DNA purification 
After PCR, or restriction digest, DNA was purified by gel extraction (QIAquick 
GelExtraction Kit, Qiagen) or with the QIAquick PCR Purification Kit (Qiagen) in 
accordance with the manufacturer’s instructions. The final elution volume comprised 30-
50 μL elution buffer or ddH2O. 
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2.2.5 Determination of DNA concentration 
DNA concentrations were determined by Nanodrop with absorption of 260 nm. The 
theoretical fundament for this measurement is described by the Beer-Lambert law 
(Absorption = (extinction coefficient) x (length of solution) x (concentration of solution)). 
2.2.6 Vector dephosphorylation 
To avoid religation of linearized plasmids with compatible ends, 5´ phosphate groups 
from restricted vector DNA were removed by adding alkaline phosphatase (New England 
Biolabs) according to the manufacturer’s protocol. 
2.2.7 DNA Ligation 
Ligation was performed adding 400 U/µl T4 DNA Ligase (New England Biolabs), 2 µl ligase 
buffer (NEB) and H2O up to a volume of 20 µl. Restricted plasmid DNA and the DNA 
fragment were ligated in a molar ratio of 1:5 for 3 h at room temperature. 
2.2.8 Preparation of CaCl2-competent bacteria 
5 ml of LB medium (Luria-Bertani-Broth) were inoculated with a single colony of E.coli 
DH5α and grown without the addition of antibodies in a 15 ml tube at 37 °C with shaking 
(250 rpm) overnight. On the next day 4 ml of the pre-culture were added to 400 ml fresh 
LB medium. The cells were incubated (37 °C, 250 rpm) until the OD600 reached 0.4, which 
took approximately three hours. Then, the bacterial suspension was pre-cooled on ice in 
50 ml tubes for 10 min. Subsequently, the suspensions were pelleted by centrifugation 
without break (7 minutes, 3000 rpm, 4 °C). For all remaining steps the cells were kept on 
ice and all flasks, pipette tips and tubes were pre-cooled at 4 °C. Cell pellets of 100 ml 
culture volume were resuspended in 10 ml ice-cold CaCl2 buffer and centrifuged again (5 
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min, 2500 rpm, 4 °C, no brakes). Cell pellets were again resuspended in 10 ml ice-cold 
CaCl2 buffer and incubated on ice for 30 min followed by centrifugation (5 min, 2500 rpm, 
4 °C, no brakes). Bacteria pellets were resuspended in 2ml ice-cold CaCl2 buffer and 150 
µl aliquots were snap frozen in liquid nitrogen and stored at -80 °C. 
Buffer/Solution Composition 
CaCl2 buffer 60 mM  CaCl2 
5% (w/v) Glycerol 
10 mM  PIPES 
pH 7                
LB medium 1% (w/v) Bacto tryptone 
0.5% (w/v) Yeast extract 
1% (w/v) NaCl 
pH 7.5, autoclaved 
LB agar plates   1x LB medium 
1.5% (w/v) Bacto agar, 
autoclaved 
 
2.2.9 Transformation of CaCl2-competent bacteria  
First, competent E. coli DH5α were thawed on ice for 10 min. 50 µl of thawed competent 
E. coli DH5α cells were mixed with 3 µl ligation mix and incubated for 30 min on ice. This 
allows the plasmid DNA to attach to the cell wall of the bacteria. Then cells were heated 
for 90 s at 42 °C and subsequently cooled on ice for 10 min. The heat-shock 
permeabilizes the cell membrane for a short duration, so that the plasmid DNA can enter 
the cell.  250 µl warm LB medium was added followed by incubation for 1 hour at 37 °C in 
a shacking thermoblock. 200 μl of cell suspension was plated on LB agar plates containing 
100 µg/ml ampicillin. After overnight incubation at 37 °C colonies were picked. 
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2.2.10 Plasmid DNA purification from bacteria 
Isolation of plasmid DNA from 5 ml E.coli overnight culture was carried out with the QIAprep 
Spin Miniprep Kit (Qiagen). For the purification of higher amounts of Plasmid DNA out of 
larger overnight cultures the PureYield™ Plasmid Maxiprep System (Promega) was utilized. 
Both kits were used according to the manufacturer’s protocol. The purified and endotoxin 
free plasmid DNA was used for transfection of mammalian cells. 
2.2.11 DNA Sequencing 
DNA samples were sent to Eurofins MWG GmbH (Ebersberg, Germany) for sequence 
analysis. 
 
2.3 Recombinant protein expression 
2.3.1 HEK cell transfection 
For the expression of albumin (Alb) and the fusion proteins CysC-Alb, CysC-Alb-Ruby and 
CysC-Ruby human embryonic kidney cell line (HEK) 293-EBNA cells were used. Before 
transfection HEK 293 cells were grown to a density of 1 × 106 cells /ml in FreestyleTM 293 
expression medium (Invitrogen) with 0.01% (v/v) Pluoronic® F-68 and 25 µg/ml 
Geneticin® G418. First, DNA (7.5 µg) and polyethyleneimine (PEI, 30 µl) were diluted 
separately in 500 µl OptiPro serum free medium (Invitrogen).  After mixing both solutions 
together complexes are forming at room temperature within the next 20 min due to the 
cationic binding capacity of PEI to negatively charged DNA. The DNA/PEI mixture was 
added drop-by-drop to 15 ml (1 × 106 cells/ml) cell suspension. For stabilization of the 
recombinant protein Bacto TC Lactalbumin Hydrolystae (BD Bioscience) was added after 
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24 hours incubation at 37°C. Supernatants were harvest after 4 days by centrifugation 
(1500 rpm/10 min/4°C). 
2.4 Protein analysis 
2.4.1 Purification of recombinant proteins by nickel-affinity chromatography 
Since CysC-Alb, CysC-Alb-Ruby and CysC-Ruby carry a his-tag, these proteins were 
purified by nickel-affinity chromatography. First, the cell culture supernatant was filtered 
through a 0.22 µm membrane (Millipore) to remove potential bacterial contamination.  
Then, the supernatant was dialyzed against Ni-NTA binding buffer at 4°C over night. 
Before the supernatant was applied, the HiTrap HP columns (GE Healthcare) were 
equilibrated with binding buffer. The column was washed with binding buffer, and bound 
proteins were eluted applying a linear imidazole gradient from 40 mM to 1 M imidazole 
in binding buffer. Fractions were collected and analyzed by SDS-PAGE and coomassie or 
silver staining to detect the protein of interest. The fractions that contained the protein 
of interest were pooled and concentrated. Imdidazol was removed by dialysis against the 
binding buffer. 
 
Buffer Composition 
Binding buffer 20 mM  Na2HPO4 
300 mM NaCl 
pH 7.4               
Elution buffer 20 mM  Na2HPO4 
300 mM NaCl 
Imidazole, gradient 1 M – 60 mM 
pH 7.4  
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2.4.2 Purification of recombinant protein by HiTrapTM Blue HP affinity 
chromatography  
The recombinant wild-type Alb was purified by using its interaction with the dye Cibacron 
Blue F3G-A. The supernatant was applied to HiTrapTM Blue HP coloums (GE Healthcare) 
and the purification was performed according to the manufacturer’s protocol. 
Buffer Composition 
Binding buffer 20 mM  sodium phosphate 
pH 7                
Elution buffer 20 mM  sodium phosphate 
2 M NaCl 
pH 7 
 
2.4.3 Determination of protein concentration 
The concentration of protein solutions was either assessed by a bicinchonic acid (BCA) 
assay carried out according to the manufacturer’s instructions, or by 
spectrophotometrically measurement of absorbance at 280 nm. The concentration can 
be calculated using the Beer-Lambert law:  
    c= (A280 × MW) / (є280 × l)  
(c = concentration; A = absorbtion;; MW = molecular weight; є = extinction coefficient; l = 
length of solution) 
The extinction coefficient of each protein was determined by using the ProtParam tool 
(http://us.expasy.org/tools/ protparam.htm) inserting the protein sequence obtained 
from the UniProt database (http://www.uniprot.org/). 
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2.4.4 Sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) 
Protein lysates containing equal amounts of protein were size-fractioned by denaturing 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in a discontinuous system with a 1.0 
mm thick stacking and separating gel in 1x running buffer. Both, the samples and the gel 
contain the detergent SDS, which denatures the proteins. They unfold into their 
secondary structure and get negatively charged according to their size. Protein lysates 
were mixed with 5x loading buffer and boiled for 5 min at 95 °C before loading onto the 
gel. For analysis, 10 to 20 µl of sample and 5 µl of protein marker (Prestained Protein 
Marker, Broad Range, New England Biolabs) were loaded. 
12 % polyacrylamide gel (8 gels) 
 
 Stacking gel Resolving gel 
H2O 13.6 ml 13,4 ml 
1.5 M Tris HCl, pH 8.8   10 ml 
1 M Tris HCl, pH 6.8 2.6 ml   
20 % SDS 100 µl 200 µl 
30 % polyacrylamide 3.3 ml 16 ml 
TEMED 200 µl 400 µl 
10% APS 20 µl 16 µl 
 
 
Buffer Composition 
10 × Running Buffer     250 mM Tris HCl 
1.92 M Glycine 
1 % (w/v) SDS                
4 x Reducing Loading Buffer 200 mM Tris HCl, pH 6.8 
40% (v/v) Glycerin  
10% (w/v) SDS 
30% (w/v) β-mercaptoethanol 
0.2% (w/v) Bromphenol blue 
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2.4.5 Protein detection 
2.4.5.1 Coomassie staining 
After SDS-PAGE gels were incubated for 1 h in Coomassie staining solution to visualize 
the protein of interest. To remove unspecific staining the gel was incubated in Coomassie 
destaining solution until protein bands were visible. The gels were photographed with a 
Chemidoc imaging system (Bio-Rad). 
Solution Composition 
Comassie staining solution 0.25% (w/v) Coomassie Brilliant 
Blue 
45% (v/v) Methanol 
10% (v/v) Acetic acid               
Comassie destaining solution 45% (v/v) Methanol 
10% (v/v) Acetic acid 
 
2.4.5.2 Silver staining 
For the detection of proteins by silver nitrate staining, gels were incubated in fixation 
solution for 1 h at room temperature while shaking. Subsequently, it was washed three 
times in 50% ethanol for 20 min and then the gel was incubated in thiosulfate solution 
for 1 min for sensitization. Then the gel was rinsed with tap water three times, incubated 
with silver nitrate solution for 20 min and developed until the bands became visible. The 
staining reaction was stopped in 50% methanol for 20 min. After the stopping solution 
was replaced with tap water, the gels were photographed with a Chemidoc imaging 
system (Bio-Rad). 
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Solution Composition 
Fixation solution 50% (v/v) Methanol 
12% (v/v) Acetic acid 
 0.5 ml/l 37% Formaldehyde               
Thiosulfate solution       0.2 g/l Na2S2O3 × 5 H2O 
Silver nitrate solution 2 g/l AgNO3 
750 ml/l 37% Formaldehyde 
Development solution 60 g/l Na2CO3 
4 mg/ml Na2SO3 × 5 H2O 
 
2.4.6 Enzymatic activity measurement 
Enzymatic activities were measured using Förster resonance energy transfer (FRET) with 
specific FRET-substrates. The substrates consist of a quencher and a fluorescence group. 
Once the peptide is cleaved internally, quencher and fluorescence group are separated 
and the hydrolysis rate of the FRET substrate by the protease is measured over time.  
The TAMRA-FRET and AMC-FRET substrates were diluted in DMSO to reach a 
concentration of 100 µM.  
Typical reaction: 
Component Volume Final 
concentration 
Activity assay buffer 40 µl  
Protease (1 µM) 5 µl 0.1 µM 
Substrate (100 µM) 5 µl 10 µM 
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Buffer Composition 
Activity assay buffer 50 mM Tris 
150 mM  NaCl 
0.01% Triton X-100 
pH 8              
 
2.4.6.1 Activity measurement assays 
The enzymatic activities of the serine proteases, PR3 and NE, were determined using 
TAMRA-FRET or ABZ-FRET substrates. For the specific mouse PR3 substrate, TAMRA-
GVRRVVQVQD-Dap (CF), fluorescence was measured at λEx = 485 nm and λEm = 520 nm. 
This substrate was synthesized by Oliver Schilling based on unpublished data. Activity 
measurements for NE were carried out with Abz-GAVVASELR-Y-(NO2)-D and the 
fluorescence was obtained at λEx = 320 nm and λEm = 405 nm.  
The enzymatic activity of CatB in mouse samples was measured using the mouse specific 
CatB substrate Z-Arg-Arg-AMC at λEx = 360 nm and λEm = 440 nm. The slope of the 
reaction curve was used to define the enzymatic activity in relative fluorescence units 
(RFU). 
2.4.6.2 Assay for CysC-Alb and CysC inhibitory activity measurement 
Inhibitory activities of CytC-Alb and CytC were tested in an activity assay using 0.1 µM 
recombinant human catepsin S and B. The remaining activity of these proteases was 
determined using the CatS specific FRET-substrate Z-Val-Val.Arg-AMC and Z-Arg-Arg-AMC 
which is specific for CatB  at 0.1 nM. 
  
    2. Materials and methods 
41 
 
Buffer Composition 
Cathepsin activity assay buffer Acetic acid 20 mM 
NaCl 150 mM 
DTT 1 mM 
EDTA 1 mM, pH 5.5 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
2.5 Mouse model analysis  
2.5.1 Mouse strains 
Pathogen-free C57BL/6J mice were obtained from Charles River. PR3/NE knockout 
animals (Ela2-/-Prtn3-/-) were established by Pfister et al. (38). Mice were backcrossed for 
more than ten generations with C57BL/6J mice. All animals were kept under normal 
housing conditions with constant temperature and humidity, a 12 hour light cycle, and 
food and water were allowed ad libitum. 
2.5.2 Study approval 
All animal experiments were conducted under strict governmental and international 
guidelines and were approved by the local government for the administrative region of 
Upper Bavaria (Project 55.2–1-54-2532-120-2015). 
2.5.3 Orthotopic lung transplantation model  
Orthotopic LTx was performed as described by Krupnick et al. with minor modifications 
(39). Male 8-12 weeks old C57BL/6J mice were utilized as donors and recipients. In brief, 
donors were anesthetized with a intraperitoneal injection of ketamine/xylazine. The 
pulmonary artery (PA), bronchus (BR) and pulmonary vein (PV) were separated with 
blunted forceps, prior to cuffing with, 24G, 20G and 22G cuffs, respectively. The left lung 
lobe was perfused intravenously with Perfadex (3 ml). Subsequently, it was perfused with 
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Perfadex alone or supplemented with 0.40 µg/ml CysC-Alb or Alb. The PA and PV were 
clamped with Biemer micro vessel clips (Bbraun), in order to keep the solution inside the 
blood vessels, and it was stored for 18 hours at 4°C before implantation. The recipient 
was anesthetized with a medetomidine/midazolam/fentanyl (1/0.05/0.02 mg/kg), 
intubated, and connected to a small animal ventilator (Harvard Apparatus), at a 
respiratory rate of 120 bpm and a tidal volume of 300 μL. The chest was incised on the 
left side between rib 3 and rib 4 and the native left lobe of the mouse lung retracted with 
a clamp. The hilar structures were carefully separated with blunted forceps. The donor 
lung graft, prepared 18 hours earlier, was perfused intravenously with Perfadex to rinse 
out the storage solution. After arrest of the blood and air flow towards the left lung, the 
cuffed graft PA, BR and PV were inserted into the recipient counterparts, and the 
connection was secured with 9-0 sutures. The native left lung was removed and the 
incision in the chest was closed with a 6-0 suture, after removing all potential air bubbles 
from the chest. After administration of antagonist the animal was extubated at the first 
signs of spontaneous breathing. After the operation, the recipients were allowed to 
recover at 30 °C and received buprenorphine (0.1 mg/kg). The mice were sacrificed four 
hours after transplantation for PGD assessment. 
2.5.4 Ex vivo lung perfsusion (EVLP) 
In order to perform EVLP, three chambers were prepared; the inflow chamber (IC), the 
lung chamber (LC) and the outflow chamber (OC). All three chambers were filled with 
Perfadex and the IC was kept at 37°C on the water bath. The donor lung was harvest 
following intubation with a 20G cannula and perfusion through the pulmonary vein with 
a 26G cannula. Then the ventilation cannula was connected to the bronchus, the inflow 
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perfusion cannula to the pulmonary artery and the outflow cannula to the pulmonary 
vein.  After putting the lung in the LC, the perfusion system was started by turning on the 
peristaltic pump (0.35ml/min) that is placed between the IC and the LC, and the 
ventilation system (80 strokes/min). Observed air bubbles in the pipeline were removed 
by using an air purge stopcock. The Perfadex solution containing either CysC-Alb or Alb 
was run through the lung scaffold for 2 h. A second peristaltic pump between the LC and 
the OC was turned on to collect the Perfusate in the OC overtime. In total 42 ml of 
Perfusate was collected in the OC after 2h EVLP. 
 
 
Figure 8: Ex vivo lung perfusion system. Once the lung is connected to a ventilation 
system (80 strokes/min) via the bronchus and the inflow and outflow cannulas via the 
pulmonary artery and vein, the lung is placed in a chamber containing Perfadex. 
Perfadex, which is kept at 37°C in the inflow chamber, reaches via a pump (0.35 ml/min) 
the lung through the pulmonary artery and is flushed out through the pulmonary vein in 
the lung chamber. The perfusate is then collected via a second pump in the outflow 
chamber. Perfadex contained 40 µg/ml CysC-Alb or Alb in our experimental setting. 
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2.5.5 Allograft tissue sample collection (blood gas, bronchoalveolar lavage) 
The recipient was anesthetized with a mixture of medetomidine/midazolam/fentanyl 
(1/0.05/0.02 mg/kg) 4 hours after LTx. After intubation (300 µl room air/120 
strokes/min), a midline abdominal incision was executed and the chest opened to expose 
the lung and heart. The right bronchus and pulmonary vein were clamped for 5 min (75 
µl room air /120 strokes/min) to determine the oxygenation function of the transplanted 
left lung by measuring the pO2 [%] of the blood from the left ventricle using a blood gas 
analyzer (ABL80 FLEX CO-OX analyzer, Radiometer). With the right bronchus still 
clamped, bronchoalveolar lavage (BAL) of the transplanted left lung was collected by 
instilling cold PBS (three times, 200 µL) into the trachea. The BAL fluid (BALF) was 
obtained by centrifugation (400 g, 20 min, 4°C) and protein concentration was measured 
with the Pierce™ BCA Protein Assay Kit (catalog no. 23225, Thermofisher). 30.000 cells 
from the BAL cell pellet were used for a cytospin (200 x g, 6 min, 4°C) and stained with 
May Grünwald (1424, Merck) and Giemsa (Merck, 9204) solution in order to perform a 
differential cell count. The lower part of the lung was kept separately for protein analysis 
(snap freezing, storage at -80 °C) and the remaining upper part was utilized for histology 
(inflation with and storage in 4% PFA). 
2.5.6 Isolation of polymorphonuclear neutrophils (PMNs) from the bone marrow 
After sacrificing the mice, bone marrow (BM) leucocytes were isolated from both femurs. 
The BM was flushed out with 10 ml RPMI medium using a syringe with a 21-gauge 
cannula and send through a cell strainer. The suspension was carefully underplayed with 
10 ml 62.1% Percoll (GE Healthcare) in 2 × HBSS and centrifuged at 500 ×g for 30 min. 
The cell pellet containing PMNs and erythrocytes was lysed with erythrocyte lysis buffer 
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(9 ml 0.16 M NH4Cl + 1 ml 0.17 TrisHCl, pH 7.5). The remaining PMNs were washed with 
ice-cold PBS and resuspended in 1ml PBS for counting.  
2.5.7 Preparation lung lysates for western blot analysis  
Whole lung tissues from the transplanted left lungs were homogenized to fine tissue 
powders of each lung. The whole lung powder was lysed in cold RIPA buffer containing 
1× phosphatase- and 1× proteinase inhibitor cocktail. Samples were left on ice for 15 
min, followed by sonification for 5 min (×4). Cell debris and DNA were pelleted and 
removed by centrifugation (10 min, 20000 x, 4 °C). The total protein concentration was 
measured by Pierce™ BCA Protein Assay Kit (23225, Thermofisher).  
 
Buffer Composition 
RIPA Buffer Tris 50 mM 
NaCl 150 mM    
Deoxycholic acid 0.5% (w/v) 
SDS 0.1% (w/v) 
Nonident P-40 (Igepal) 0.5% (w/v) 
EDTA 1 mM 
pH 8.0         
 
2.5.8 Lung tissue preparation for staining of lung sections 
Left mouse lungs were inflated with 4% PFA through an intratracheal cannula at the time 
of sacrifice, the trachea was ligated, and the lungs were fixed in 4% PFA, at 4°C overnight, 
and transferred to 70% ethanol before paraffin-embedding. The grafts were 
subsequently embedded in agarose, and cut into 3 pieces, and then separated 3 mm 
from each other. The pieces were embedded in paraffin, and then sliced into 3 µm-thin 
sections with a microtome (Hyrax M55, Zeiss).  
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For immunofluorescence stainings, lungs were frozen after EVLP and embedded in 
optimal cutting temperature (O.C.T) compound (Scigen). 3 µm-thin sections were cut 
with a cryotome (CM3050, Leica). 
 
2.6 Cell biological methods 
2.6.1 Cell lines 
The cell line HEK 293 EBNA1 was purchased from the NRC Biotechnology Research 
Institute (National Research Council in Montreal, Canada), and the murine macrophage-
like cell line RAW264.7 derived from Balb/C mice from Sigma-Aldrich (Missouri, USA). 
2.6.2 Culturing of HEK 293 EBNA1 and RAW264.7 cells 
HEK 293 EBNA1 were seeded at 0.2 × 106 cells and cultured in FreestyleTM 293 
expression medium (Invitrogen) with 0.01% (v7V) Pluoronic® F-68 and 25 µg/ml 
Geneticin® G418 in suspension. RAW264.7 were seeded at 2 × 105 cells and cultured in 
DMEM; F12, (+ 1% Pen/Strep, 10 % FCS) at 5% CO2, 37°C. Cells grown adherent and were 
dislodged from the flask with a cell scraper for subculturing. 
2.6.3 Determination of cell count and viability 
A hemocytometer (Neubauer improved) was used to count the number of viable cells. 
For this purpose 10 µl of cell suspension were mixed with 10 µl Trypan blue buffer and all 
viable cell were counted in the four quadrants. Dead cells have perforated membranes; 
Trypan blue can enter into the cytoplasm and stains these cells blue. The average 
number of cells in one quadrant (100 nl) was multiplied with the dilution factor and by 
104 to determine the number of cells/ml. 
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Buffer Composition 
Trypan blue buffer Trypan blue 0.1% (w/v) 
PBS 
pH 7.4 
 
2.6.4 Live cell imaging of RAW264.7 cells 
4 × 104 cells were seeded on 170 µm imaging dishes (Eppendorf) in culturing medium and 
cultured for 18 h. Adherent cells were washed with PBS for 5 min prior to staining. 
LysoTracker (1:1000), Hoechst (1:10000) and CysC-Ruby (40µg/ml) or CysC-Alb-Ruby 
(40µg/ml) were added to culturing medium without FCS and incubated for 2 hours at 
37°C. Cells were washed 3 times with PBS for 5 min and immunofluorescence was 
examined with a confocal microscope (LSM 710, Zeiss). Fluorescence confocal mirroscopy 
were recorded under triple fluorescent mode in which cells were successively exposed to 
647 nm, 460 nm and 568 nm. 
2.6.5 In vitro model of cold ischemia and simulated EVLP/Reperfusion 
In vitro modeling of cold ischemia and simulated EVLP/Reperfusion was developed as 
described by Casiraghi et al. with modifications mimicking our in vivo LTx model (40). 
RAW264.7 were seeded at a density of 2 × 105 and grown in culturing medium for 24h at 
37°C. They underwent cold ischemia by replacing 37°C medium with 4°C Perfadex for 
18h. To determine the effect of CysC-Alb, either CysC-Alb or Alb was supplemented to 
Perfadex. To imitate EVLP (2 h) and reperfusion (4 h) dishes were warmed up to 37°C for 
6h. Perfadex supernatant and cells were collected for subsequent analysis. 
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2.6.6 Apoptosis 
Apoptotic cell death was analyzed by terminal deoxynuleotidyl transferase-mediated 
dUTP nick end labeling using the Apoptosis Detection System (DeadEnd Fluorometric 
TUNEL, Promega). Cells in 24-well plates were treated according to the manufacturers’ 
instructions. For quantitative analysis, the number of TUNEL positive nuclei in 24-well 
plates was counted. 
2.6.7 Cell viability 
Cell viability was analyzed by using a cell counting Kit (Cell Counting Kit-8, Biotool) that 
used the tetrazolium salt WST-8 to produce a water-soluble formazan dye by the 
dehydrogenases in the cells. For quantitative analysis, the absorbance was measured at 
450 nm using a microplate reader. 
2.6.8 Preparation of total cell lysates 
For the lysis of PMN, cells were resuspended in cold RIPA (radioimmunoprecipitation 
assay) buffer (12 µl/106 cells). After incubating on ice for 20 min the samples were 
centrifuged (10 min, 4 °C, 20 000 x g). Cell debris and DNA remained in the pellet, while 
the supernatant was transferred to a new tube.  
RAW264.7 cells were washed 2× with PBS and scratched with RIPA containing 1× 
protease inhibitor cocktail and 1× phosphatase inhibitor (Roche). After incubation on ice 
for 30 min, lysate was centrifuged at 13000 rpm for 5 min and supernatant was 
transferred to a new tube. 
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2.7 Immunological methods 
2.7.1 Immunoblotting 
For immunoblotting, proteins were transferred onto a polyvinylidene difluoride (PVDF) 
membrane by semi-dry electro blotting. The membrane was shortly immersed in 
methanol and incubated for 5 min together with the gel in blotting buffer. The transfer 
was carried out between four sheets of transfer buffer soaked Whatman paper at 200 
mA for 50 min. The membrane was then blocked with 5 % fat dried milk or 1 × RotiBlock® 
(Carl Roth) for 1 h at room temperature, followed by incubation with the primary 
antibody diluted in blocking buffer overnight at 4°C. After washing the membrane three 
times for 10 min with PBS-T at room temperature to remove unbound antibody, the 
membrane was incubated with a specific (second) antibody conjugated to a horseradish 
peroxidase (HRP). After incubation for 1 hour at room temperature, the membrane was 
washed three times with PBS-T. Proteins were detected with the Super Signal® West Pico 
Chemiluminescent Substrate (#34080, Thermo Scientific). 750 µl of both Solution A 
(Luminol Enhancer Solution) and Solution B (Stable Peroxide Solution) were mixed and 
immediately added to the membrane for a two min incubation. The membrane was 
developed by using the Chemidoc imaging system (Bio-Rad). All western blot protocols 
are listed in below. 
Buffer Composition 
Transfer Buffer 25 mM Tris 250 mM   
Glycine 1 mM SDS 
20% MeOH 
Blocking milk 1 × PBS-T 
5% (w/v) Non-Fat dry Milk Blocker 
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Protocols for western blots: 
Blocking solution  primary AB    secondary AB    
 
1 × RotiBlock®   NE, rabbit monoclonal  goat anti-rabbit,   
     1:1000, 4°C on   1:20000 
1 × RotiBlock®   PR3, goat serum   mouse anti-goat,  
     1:1000, 4°C on   1:40000  
  
1 × RotiBlock®   CysC, rabbit monoclonal   goat anti-rabbit,  
     1:10000, 4°C on   1:20000 
1 × RotiBlock®   AAT, rat monoclonal    goat anti-rat, 1:40000 
     1:1000, 4°C on   
1 × RotiBlock®   cleaved Caspase3, rabbit  goat anti-rabbit,  
     monoclonal, 1:1000, 4°C on  1:20000 
 
2.7.2 Enzyme-linked immunosorbent assay (ELISA) 
ELISAs were performed for the detection of inflammatory cytokines and neutrophil 
elastase in BALF, cell lysates and whole tissue lysates using the following specific 
commercial available kits. 
Kit Supplier 
Mouse Inflammatory Cytokine Multi-Analyte 
ELISArrayTM Kit 
Qiagen, Hilden, 
Germany 
Mouse Elastase/ELANE/ELA2 PicoKlineTM 
ELISA Kit 
BosterBio, Pleasanton, 
USA 
Murine TNF-α Standard ABTS ELISA 
Development Kit 
PeproTech, Hamburg, 
Germany 
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In principle the two kits work like a so called sandwich ELISA. The 96 well plates were 
already pre-coated with the specific target antibody to capture the desired protein from 
the sample. The detection antibody was either a biotinylated antibody or a horseradish 
peroxidase (HRP) coupled antibody against the specific protein of interest. For the 
development of the ELISA TMP substrate was added and the absorbance was read with a 
microplate reader at 450 nm. 
2.7.3 Immunological staining of lung tissue 
Immunofluorescence staining was performed with paraffin and frozen lung tissue 
sections of the transplanted left lung 4h after reperfusion. 
2.7.3.1 Deparaffinization 
Paraffin sections containing lung tissue slices were incubated for 20 minutes at 65 °C. 
Then they were sequentially transferred to 100% xylene, then 100%, 90%, 80% and 70% 
ethanol, followed by tap water for 5 min, and rinsed in distilled water. Antigen retrieval 
was performed in 0.01 M citric acid pH 6.0 in a cooker chamber for 30 minutes at 125°C. 
Tissue was rehydrated with PBS-Tween 20 (0,1%) for 10 min.  
2.7.3.2 Immunohistochemical stainings 
Hematoxylin and eosin staining 
Sections were stained with Hematoxylin (Hematoxylin solution, GHS-232, Sigma Aldrich) 
for 6 min, rinsed in distilled water, and tap water for 15 min, followed by distilled water. 
Then they were stained with eosin for 10 min and washed in tap water for 5 min. 
Subsequently, sections were dehydrated with ethanol 100% and xylene, and mounted 
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with glue (Entellan, Merck). For visualization the slides were were scanned with Myrax 
Desk.  
Peroxidase staining 
Endogenous peroxidases were quenched by incubation in 3% H2O2 (30%, H1009, Sigma 
Aldrich) in PBS for 10 min. After washing with PBS and PBS-Tween 20 (0,1%) avidin 
solution (Avidin/Biotin Blocking Kit, SP-2001; Vector Laboratories) was added and 
incubated for 15 min, followed by washing with PBS-T (1x PBS-Tween 20 0,1%); biotin 
solution was added for 15 min, washed with PBS-T; nonspecific antibody-binding sites 
were blocked with blocking solution, PBSA (BSA 3% in PBS) for 1 h, and sections were 
incubated for 1.5 h with the specific primary antibody diluted in blocking buffer. Sections 
were stained with monoclonal rat mouse-specific Ly-6G monoclonal antibody (working 
dilution 1:200, clone 1A8, Biolegend) for detection of neutrophils. After washing in PBS-T, 
visualization was performed via incubation with HRP-conjugated secondary antibody 
with goat rat-specific IgG (H+L), biotin conjugated (working dilution 1:250, Thermofisher) 
for 30 min at room temperature followed by addition of the corresponding peroxidase 
substrate (ImmPACT DAB Peroxidase (HRP) Substrate, SK-4105; Vector Laboratories). 
After counterstaining with hematoxylin, dehydration and mounting, the sections were 
scanned using the Axio Imager (Imager.M2, Zeiss). High resolution images, which were 
taken at the same magnification and areas were randomly chosen and microscopically 
analyzed for neutrophil counting. The mean number of at least ten images was used for 
quantification. 
    2. Materials and methods 
53 
 
2.7.3.3 Immunofluorescence staining 
Immunofluorescence staining is based on the fundamentality of antigen-antibody binding 
reaction. Antigens are visualized by fluorescence dyes conjugated with antibodies when 
activated by light of specific wavelength under the fluorescence microscope. Before 
staining, frozen tissue sections were fixed in 50% methanol/50% acetone for 20 min at -
20°C. In order to exclude a signal due to unspecific binding of the secondary antibody, a 
negative control was performed for each staining where no primary antibodies were 
used. The lung sections were stained with either NE, Gal3, pro-SPC, Ly-6G (Research Unit 
Analytical Pathology, HMGU, München) or LAMP2. All staining protocols are listed in 
below.  
Protocols for immunofluorescence staining 
Blocking solution  primary AB   secondary AB     
 
3% H2O2, 10 min  Ly-6G, rat   goat-anti-rabbit, 1:500  
 0.1% Triton, 1x TBS,   1:200, 4°C on   Alexa Fluor® 645 
45 min        1:1000, 1h @RT 
 5% BSA, 0.3% Triton,  NE, rabbit    Cy3-goat anti-rabbit, 1:100 
1x TBS , 1 h   1:400, 4°C on 
         
 5% BSA, 0.3% Triton,  Gal3, mouse   goat-anti-mouse Alexa  
 1x TBS , 1 h       Fluor® 488, 1:500  
    
5% BSA, 0.3% Triton,  Pro-SPC, rabbit  goat-anti rabbit, 1:500 
1x TBS , 1 h       Alexa Fluor® 488 
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2.7.4 RNA analysis 
2.7.4.1 RNA isolation 
Total RNA from RAW264.7 cells was isolated using the peqGold total RNA kit (VWR) 
according to the manufacturer’s protocol. RNA was stored at – 80°C until further use. 
Table 12: Real-time PCR program 
 
Step  Temperatures  Periods Cycles 
1  94°C   2:00    
2  94°C   0:20  
3  60°C   0:10  40x 
4  79°C   0:20 
5  95°C   1:00 
6  55°C   1:10 
7  55°C   0:06  80x 
 
 
2.8 Microscopy 
Immunological staining of left lung sections were analyzed with the Axio Imager Z1-
microscope. Images were evaluated using the commercially available image analysis 
software Definiens Developer XD 2 (Definiens AG, Munich, Germany). 
2.9 Statistics  
All results are expressed as mean ± SEM. Group comparisons were determined by One-
way Anova, student’s t-test or unpaired Mann-Whitney U-test using the commercially 
available statistical software GraphPad Prism version 5.0. Statistical significance was 
defined as p ≤ 0.05.  
. 
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3. Results 
3.1 CysC-Alb in LTx - Results 
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CysC is an endogenous small peptide inhibitor with a broad reactivity against cysteine 
proteases including CatS, CatL and CatB. To enhance the quality of CysC, it was fused 
directly to the N-terminus of Alb. The N-terminal end of CysC is critical for its tight 
enzyme-binding property and therefore important for effective inhibition of cysteine 
proteases (57). For monomer stabilization, we have introduced an additional third 
disulfide bond (CysC47-CysC69). DNA sequences can be found in the appendix. 
3.1.2 Production of CysC-Alb and Alb in HEK 293E cells 
CysC-Alb and Alb were successfully expressed in HEK 293E cells using the pTT5 expression 
vector. The cells were transfected with 1:1 CysC-Alb and harvested routinely after 4 days. 
High amount of protein was secreted into the supernatant. A Igκ-signal peptide was used 
in the construct for secretion into the cell culture supernatant. Using a C-terminal His-
tag, CysC-Alb was purified with Ni-NTA affinity chromatography (Figure 9A). After 
purification, the CysC-Alb elution fractions yielded only few other proteins, with a minor 
contaminant considered to be Alb (67 kDa), which may originate from dead cells. The 
highest yield of CysC-Alb was 10 mg and was obtained from 600 ml cell culture volume. 
Alb was purified via HiTrapTM Blue HP affinity chromatograph by using its interaction with 
the dye Cibacron Blue F3G-A (Figure 9B). 8 mg was the highest yield of Alb, which was 
obtained from 600 ml cell culture volume. 
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Figure 9: Production of CysC-Alb and Alb in HEK 293E cells. Coomassie staining of cell 
culture supernatants and purified elution fractions after transfection of HEK 293E cells 
with CysC-Alb or Alb. The CysC-Alb construct contains an Igκ-signal peptide for secretion 
into the cell supernatant and a C-terminal his-tag for purification, whereas the Alb 
construct contains no his-tag. The sequences are listed in the appendix. (A) CysC-Alb was 
purified from 300 ml supernatant by Ni-NTA chromatography and eluted from the Ni-
columns with an Imidazole gradient (40 mM, 60 mM, 75 mM, 150 mM, 300 mM, 500 
mM, 1 M). (B) Alb was purified from 300 ml by HiTrapTM Blue HP affinity chromatography 
and eluted with 2 M NaCl. The volume of each elution fraction was 1.5 ml. 15 µl of the 
supernatant, the wash (with 20 mM Na2HPO4, 300 mM NaCl pH 7.4), the flowthrough 
and the elution fractions were analyzed on a SDS-PAGE. (SN = supernatant, F = 
flowthrough, W = wash). 
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3.1.3 Production of further CysC variants 
CysC-Alb and CysC were extended at their C-terminus with the fluorescence protein, 
ruby, to visualization studies in vitro. Ruby is a monomeric red fluorescence protein 
isolated from marine invertebrates and characterized as highly resistant to denaturation 
at extreme pH (58). As described above, both fusion proteins were expressed in HEK 
293E cells by using an Igκ-signal peptide for secretion and a C-terminal his-tag for Ni-
affinity chromatography purification (Figure 10A). The fluorescence proteins, CysC-Alb-
Ruby and CysC-Ruby were well expressed in HEK 293E cells and could be isolated from 
the supernatant relatively pure with only little contamination probably by degradation 
products (Figure 10B, C).  
 
Figure 10: Production of further CysC variants. The pTT5/HEK293 expression system was 
used for recombinant production of CysC-Alb and CysC fused to the fluorescence protein, 
ruby. (A) The construct contains a C-terminal his-tag for purification and an Igκ-signal 
peptide for secretion into the cell culture supernatant. In both constructs, the 
fluorescence protein ruby has been placed N-terminal to the his-tag. The sequences are 
listed in the appendix. (B, C) 2 µg of purified proteins were separated by SDS-PAGE (12% 
gel) and stained with Coomassie. 
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3.1.4 Functional analysis of CysC-Alb 
3.1.4.1 Edman Sequencing 
After Ni-chromatography purification, CysC-Alb was send to Beate Jaschok-Kentner 
(Helmholtz Zentrum für Inektionskrankheiten, Braunschweig) for Edman sequencing in 
order to confirm a full length N-terminus of CysC in the CysC-Alb fusion protein. As 
already mentioned before, the two N-terminal amino acid residues are necessary for the 
tight binding of CysC to cysteine proteases and are therefore needed for successful 
inhibition. Figure 11A shows an interaction model of chicken CysC with papain, which is 
exemplary for the interaction of cysteine proteases with CysC. Expression of full length 
CysC-Alb was unsuccessful with the initial mouse CysC-Alb construct, as it was shortened 
by 5 amino acid residues at the N-terminus, most likely due to exopeptidase cleavage. 
Therefore, a second construct was designed in which the N-terminal amino residues of 
the mouse CysC construct were exchanged by the N-terminal amino acid residues of 
chicken CysC (Figure 11B), that are considered to be less prone to exopeptidase cleavage. 
As a result, we were able to express and purify clean CysC-Alb with a correct N-terminus 
verified by Edman sequencing (Figure 11C). 
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Figure 11. Full length CysC-Alb amino acid sequence was approved by Edman-
sequencing. (A) Scheme of the “trunc model” for the interaction of chicken CysC with 
papain. The two lysines before the first glycin are crucial for the tight binding of cystatin 
C to papain. (B) Alignment of our recombinant mouse CysC (rmCysC) and chicken CysC 
(gCysC). rmCysC and gCysC share high sequence homologies. mCysC contains naturally 
two disulfide bonds (red), a third disulfide bond (green) was introduced for monomer 
stabilization. (B) For Edman Sequencing, 60 pmol CysC-Alb was run on a 12 % SDS gel and 
blotted on a PVDF membrane using natriumcarbonat transferbuffer without glycine. The 
membrane was stained with coomassie blue for 30 sec and CysC-Alb was analyzed for a 
full-length N-terminus by Edman sequencing. 
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3.1.4.2 Inhibitory activity of CysC-Alb 
CysC is the endogenous inhibitor of the cysteine proteases CatB, CatL, Cat H, CatS (59). 
Since CatS and CatB were considered to be the most crucial cysteine proteases in the 
planned experiments, enzymatic activities of these two proteases were measured with 
CysC-Alb in a FRET-substrate based assay in order to ensure that CysC still contains its 
inhibitory activity after fusion to Alb. The inhibition of CatS and CatB was tested with 
different concentrations of CysC-Alb and compared to the inhibition of CatS and CatB by 
CysC (Figure 12A-D). Cys-Alb and CysC inhibited CatS and CatB partially at 
substoichiometric concentrations and fully with a slight molar excess of the inhibitor. The 
initial linear regression was used to calculate the concentration for CysC-Alb and CysC 
needed to inhibit 0.1 µM CatS or 0.1 µM CatB (Figure 12E).  
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Figure 12: CysC-Alb and CysC inhibit CatS and CatB in a similar manner. To estimate the 
concentration of CysC-Alb or CysC needed to inhibit CatS or CatB, (A, B) 0.1 µM 
recombinant CatS and (C, D) 0.1µM recombinant CatB were incubated with varying 
amounts of CysC-Alb or recombinant CysC. The residual activity was measured by adding 
10 µM of FRET-substrate (CatS: Z-Val-Val-Arg-AMC, CatB: Z-Arg-Arg-AMC) at 
extinction/emission = 360/440. Data was plotted as relative fluorescence units (RFU) 
versus time [min] for each sample and one representative example of three technical 
repeats is shown. (E) The linear regression of the initial time points during which the 
reaction is linear was used to obtain the concentration of CysC-Alb and CysC needed to 
inhibit 0.1 µM CatS or 0.1 µM CatB.  
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3.1.4.3 Macrophages internalize CysC-Alb-Ruby 
CysC-Alb-Ruby and CysC-Ruby were especially developed and produced for imaging 
studies of the inhibitor CysC-Alb. Hence, to investigate whether macrophages internalize 
CysC-Alb, the fluorescent protein CysC-Alb-Ruby was used. RAW264.7 cells were 
incubated with 40 µg/ml CysC-Alb-Ruby at 37°C for 2 h. Immediately thereafter, live cell 
imaging was performed by bright field and fluorescence microscopy. Indeed, 
macrophages internalized CysC-Alb-Ruby after 2 h incubation (Figure 13). 
 
Figure 13: Macrophages internalize CysC-Alb-Ruby. Macrophages were treated with 40 
µg/ml CysC-Alb-Ruby in culture medium for 2h at 37°C. Macrophages were visualized by 
bright field imaging and CysC-Alb-Ruby by fluorescence imaging 
(Excitation/Emission=558/605), and images were merged. Magnification is indicated as 
62x, scale bars = 20 µm 
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3.1.4.4 CysC-Alb is protected from lysosomal degradation in macrophages 
To analyze the advantage of the CysC-Alb fusion protein over CysC, macrophages were 
incubated with a lysotracker and localization of CysC-Alb-Ruby was compared with CysC-
Ruby. Live cell imaging of macrophages using a confocal microscope clarified that CysC-
Alb-Ruby is protected from lysosomal degradation by the FcRn-mediated recycling 
mechanism in macrophages. CysC-Alb-Ruby (red) was not collocated with the signal of 
the lysotracker (green). In comparison CysC-Ruby was clearly located in lysosomes as 
indicated as a bright yellow signal due to the double fluorescence signal of CysC-Ruby 
and the lysotracker (Figure 14). 
 
Figure 14: CysC-Alb is protected from lysosomal degradation. Simultaneous visualization 
of lysosomes (green) by fluorescent labeling and use of CysC-Alb-Ruby or CysC-Ruby (red) 
in macrophages. Macrophages were seeded onto imaging dishes and incubated with 
lysotracker (1:1000) and CysC-Alb-Ruby or CysC-Ruby (40 µg/ml) in serum free culturing 
medium for 2 h. Cell nuclei were stained with Hoechst (blue, 1:10000). Shown are 
representative fields of live cell imaging by confocal microscopy. Magnification is 
indicated as 63x, scale bars = 10 µm. 
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3.1.5 CysC-Alb graft preservation in a murine model of LTx 
In order to investigate if lung storage in Perfadex containing CysC-Alb protects the graft 
from cysteine protease mediated graft damage during cold storage and reperfusion, an 
orthotopic LTx model was used. As EVLP is experimentally used in clinical research to 
reassess and regenerate donor lungs before LTx, we additionally combined this method 
with our experimental approach (Figure 15). The orthotopic LTx was performed by 
Natalia Smirnova (iLBD, Helmholtz Zentrum München). 
 
 
Figure 15: Lung graft preservation, EVLP and lung transplantation procedure. 
Experimental outline for storage in Perfadex containing 40 µg/ml CysC-Alb or Alb during 
cold ischemia (18h, 4°C) and ex vivo lung perfusion (EVLP, 2h, 37°C), followed by lung  
transplantation (LTx) and reperfusion (4h, 37°C). 
 
3.1.5.1 CysC-Alb is detectable in lung tissue 4 h after reperfusion 
To inhibit lysosomal cathepsins in the extracellular space, CysC-Alb needs to diffuse in the 
perivascular and interstitial space during CS and EVLP. Hence, whole lung tissue lysates 
from the transplanted lung were analyzed 4 h after reperfusion for the presence of CysC. 
The lung has been stored under cold ischemia condition and perfusion with either CysC-
Alb or Alb ex vivo. Briefly, upon perfusion with PBS to remove blood from the vessels, 
specimens of the transplanted lung lobe were collected and whole lung tissue lysates 
were run on a 12% SDS gel. Using a monoclonal CysC antibody, immunoblot analysis 
revealed the presence of CysC in lung tissue of all CysC-Alb treated lungs. No levels of 
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CysC were detected in the Alb control group. β-actin was used as an internal loading 
control (Figure 16).  
 
                             
Figure 16: CysC-Alb is present in lung tissue after LTx. Tissue samples of the transplanted 
left lung were collected 4 h after reperfusion and subsequently lysed for total protein 
analyses. 15 µg of whole protein were loaded on a 12% SDS gel followed by immunoblot 
analysis of CysC. CysC was detected in lung tissue lysates of CysC-Alb treated animals 4 h 
after reperfusion using a rabbit anti-CysC mAb (1:10000). Detection of β-actin served as 
loading control.  
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3.1.5.2 Storage of lung transplants in CysC-Alb improves lung function 
After stopping the air flow of the right lung by clamping the right bronchus, the partial 
oxygen pressure (pO2) in the left ventricle was measured to examine the potential 
beneficial effect of CysC-Alb addition to Perfadex during storage and perfusion of the 
lung transplant in the cold. CysC-Alb and Alb were directly compared at the same 
concentration (0.04 µg/ml) in our murine LTx model. As envisaged, we found a highly 
protective effect on graft preservation on the functional level. Addition of CysC-Alb to 
Perfadex resulted in an almost 30% higher blood oxygenation (Figure 17A) in the left 
ventricle. Even in the periphery increased pO2 levels compared to the control were 
observed (Figure 17B). Nevertheless, morphological studies revealed pulmonary 
hemorrhage and edema formation in both groups (Figure 17C). This was confirmed by 
assessing the wet/dry lung weight ratio after CS and EVLP, which is an index for edema 
formation (Figure 17D). The supplementation of CysC-Alb to the preservation solution did 
not suppress edema formation.  
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Figure 17: Primary graft dysfunction is reduced by CysC-Alb. Left donor lungs of 
C57BL/6J mice were stored and perfused in Perfadex supplemented with either Alb or 
CysC-Alb at 4°C for 18 h (cold storage) and 37°C for 2 h (EVLP). Recipient mice were 
sacrificed 4 h after reperfusion and the pO2 (partial oxygen pressure) was measured in 
the blood from (B) the left ventricle and (A) the vena cava after clamping the right 
bronchus for 5 min. (C) Haematoxylin and Eosin (HE) staining illustrated the morphology 
of left lung tissue after LTx (scale bars: 200 µm). (D) Lung wet/dry weight ratio of the left 
lung was measured after CS and EVLP. Data are presented as means ±SEM of 3-4 mice 
per group and compared with a Mann-Whitney test (*p ≤ 0.05) 
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3.1.5.3 CysC-Alb treatment selectively blocks TNF-α increase in the perfusate 
As we expected that CysC-Alb has an anti-inflammatory effect, perfusate samples were 
collected after 2 h EVLP and subsequently analyzed for inflammatory mediators using a 
multianalyte cytokine Elisa kit. Pro-inflammatory TNF-α was increased in the Alb control 
group after EVLP, while CysC-Alb Perfadex supplementation blocked the increase of TNF-
α in EVLP perfusate (Figure 18A). Increased Interleukin 6 (IL-6) levels were observed in 
both groups with no significant reduction after CysC-Alb treatment (Figure 18B). The 
levels of IL-1α, IL-1β, Il-4, Il-10, Il-12, Il-17A, INF-γ, G-GSF, GM-CSF were undetectable in 
perfusate after EVLP. 
 
Figure 18: Effect of CysC-Alb on inflammatory mediators in perfusates. (A) TNF-α and 
(B) IL-6 were measured in the EVLP perfusate after 2 h using a multianalyte ELISA kit. 
Data expressed as mean ±SEM of 4 mice per group and compared with a Mann-Whitney 
test (*p ≤ 0.05) 
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3.1.5.5  CysC-Alb protects from apoptotic cell death 
To further investigate the protective effect of CysC-Alb preservation supplementation, 
apoptotic cell death in lung tissue was evaluated 4 h after reperfusion. The total number 
of apoptotic cells (TUNEL) was significantly lower in lung tissue, which was preserved in 
Perfadex containing CysC-Alb during cold storage and EVLP compared to the Alb control 
group (Figure 19A/B). In order to identify the specific cell type protected from apoptotic 
cell death in the lung, double fluorescence staining of apoptotic cells (TUNEL) and 
alveolar type 2 cells (AT2, pro-SPC), as well as apoptotic cells (TUNEL) and macrophages 
(Gal3) was performed. Double immunofluorescent staining demonstrated a high number 
of AT2 cells that are affected by apoptosis (Figure 19C). Lung macrophages are similarly 
compromised as evidenced by the colocalization of TUNEL and Gal3 positive cells (Figure 
19E). Quantification of double-positive signals revealed that supplementation of Perfadex 
with CysC-Alb diminished apoptotic cell death of AT2 and macrophages (Figure 19D/F). 
Quantitative analysis was performed by counting all TUNEL positive and double positive 
cells for TUNEL/pro-SPC and TUNEL/Gal3 per field of vision in lung sections of the two 
groups.  
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Figure 19: Analysis of apoptotic cell death in lung tissue by TUNEL assay. TUNEL staining 
of lung paraffin sections was performed to quantitate the protective effect of CysC-Alb 
compared to Alb added to the lung preservation solution. (A) Apoptotic cells are marked 
in red, the nuclei of the cells are stained in blue (DAPI). (B) Number of TUNEL-positive 
cells of all fields of vision in CysC-Alb and Alb treated lungs. (C) Double fluorescent 
staining of TUNEL and pro-SPC (marker for alveolar type II cells (ATII), green), and (D) 
total cell count of TUNEL/pro-SPC positive cells in all fields of vision (FOV). (E) Double 
fluorescent staining of TUNEL and Gal3 (marker for macrophages, green), and (F) total 
cell count of TUNEL/Gal3 positive cells in all fields of vision (FOV). Values are represented 
as means ±SEM of 3-4 mice per group and compared with a Mann-Whitney test (*p ≤ 
0.05, **p ≤ 0.01, ****p ≤ 0.0001). Magnification is indicated as 20x, scale bars = 50 µm. 
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3.1.6 In vitro model of CS and simulated EVLP/Reperfusion 
To further investigate events occurring during storage and transplantation an in vitro 
model of non-hypoxic cold storage and EVLP/Reperfusion (R) simulation at 37°C was 
used, which was adapted from Casiraghi et al. (40). CS and EVLP were simulated in 
RAW264.7 macrophages by replacing culture medium with Perfadex containing either 
Alb or CysC-Alb. Following 18 h incubation at 4°C (CS), cell culture plates were rewarmed 
to 37°C for 6 h to simulate temperatures during 2 h of EVLP and the 4 h period of 
reperfusion (R) (Figure 20A). 
3.1.6.1 CysC-Alb inhibits CatB activity after CS and simulated EVLP/R  
Perfadex samples were analyzed for CatB activity following CS and simulated EVLP/R. CS 
followed by simulated EVLP/R was associated with CatB activity in Alb complemented 
Perfadex samples and non-treated Perfadex samples. CatB activity was significantly lower 
in Perfadex samples containing CysC-Alb, which correlated with the activity of CatB in the 
medium of macrophages cultured at 37°C for 24 h (corresponding to 18 h CS and 6 h 
EVLP/R) (Figure 20B). The comparison of CatB activity in Perfadex samples of 
macrophages after CS and CS followed by simulated EVLP/R revealed a significant higher 
activity of CatB after CS followed by EVLP/R (Figure 20C). 
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Figure 20: CysC-Alb reduces CatB activity after CS and stimulated EVLP/R. A) Time 
course of the in vitro modeling of CS and simulated EVLP/R. Warm medium was replaced 
by cold Perfadex (4°C) containing 80 µg/ml CysC-Alb or Alb and incubated for 18 h at 4°C. 
Following cold storage (CS), cell plates are place in the incubator at 37°C for 6 h to mimic 
temperatures during EVLP (2 h) and reperfusion (R, 4 h). B,C) CatB activity in 50 µl 
Perfadex after 18 h CS, or 18 h CS + 6 h EVLP/R was determined by a FRET-based activity 
assay. CatB activity was measured in Perfadex containing CysC-Alb or Alb with the FRET-
substrate Z-RR- AMC (10 µM) over time. Measurement of CatB activity in Perfadex 
without supplementation and medium served as controls. The initial reaction velocity 
(V0) was obtained in RFU/min by determining the slope of the linear portion of the data 
plot. Data shown are mean ± SEM of 5 replicates per group, and a two-tailed Mann-
Whitney test was used for statistical analysis. **p ≤ 0.01, ***p ≤ 0.005 
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3.1.6.2 CysC-Alb does not influence cell death in vitro 
Since CysC-Alb protected lung cells from apoptotic cell death during CS and EVLP/R in 
vivo, cell viability was assessed by MTT assay in our in vitro model of CS and simulated 
EVLP/R. Even though viability of macrophages treated with Alb and CysC-Alb containing 
perfadex was drastically decreased in comparison to macrophages cultured in medium, 
no differences in cell viability was found between macrophages treated with Alb and 
macrophages treated with CysC-Alb. In vitro CS and simulated EVLP/R resulted in a 
decreased viability of 27% in the Alb group and 29% in the CysC-Alb group compared to 
the medium control group (Figure 21A),  When viability of the different treatment groups 
(Alb and CysC-Alb) were compared between 18 h CS alone, and 18 h CS following 6 h 
simualted EVLP/R it became apparent that the viability of macrophages is significantly 
diminished after the warm up phase of EVLP and R in both treatment groups compared 
to the viability after CS alone (Figure 21B). To verify if apoptosis is a possible mechanism 
of programmed cell death, macrophages were examined for cleaved caspase 3 protein by 
WB. WB analysis showed clearly that there were no differences in cleaved caspase 3 
levels in macrophage lysates treated with Alb or CysC-Alb during 18h CS and 6h EVLP/R 
(Figure 21C, D). We thereby exclude that CysC-Alb has a protective effect in primary cell 
death events in macrophages in our in vitro model of CS and simulated EVLP/R. 
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Figure 21: CysC-Alb has no effect on cell death in vitro. Macrophages were treated with 
40 µg/ml Alb or CysC-Alb in Perfadex during 18 h CS, or 18 h CS + 6 h simulated EVLP/R at 
37°C. Cell viability was detected by MTT assay. (A) Cell viability of CysC-Alb and Alb 
treated macrophages was directly compared to macrophages cultured in medium after 
18 h CS + 6 h simulated EVLP/R. (B) Comparison of cell viability between 18 h CS and 18 h 
CS followed by 6 h simulated EVLP/R of the different treatment groups (Alb and CysC-
Alb).  (C) Representative western blot image and (D) densitometry analysis of cleaved 
caspase 3 in whole macrophage lysates after 18 h CS following 6 h simulated EVLP/R. β-
actin served as loading control. Data are shown as means ± SEM of 5 replicates per group 
and a two-tailed Mann-Whitney test was used for statistical analysis. *p ≤ 0.05 
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3.1.6.3 CatB inhibition results in the reduction of TNF-α release after CS and simulated 
EVLP/R 
To determine the levels of TNF-α released in Perfadex medium, macrophages were 
treated with Alb or CysC-Alb during in vitro CS alone and CS followed by simulated 
EVLP/R. As expected, CysC-Alb significantly reduced levels of TNF-α in Perfadex 
compared to the Alb treatment group after CS and simulated EVLP/R (Figure 22A). To 
clarify whether the reduction of TNF-α in Perfadex is a direct effect of CysC or due to 
CatB inhibition, we included a CatB inhibitor, CA-074, as treatment group during CS and 
simulated EVLP/R. In a similar manner like CysC-Alb, CA-074 treatment significantly 
lowered TNF-α in Perfadex compared to Alb after CS and simulated EVLP/R (Figure 20A). 
Furthermore, it is noteworthy that the TNF-α level in Perfadex after CS alone were 
significant lower in the Alb treatment group compared to TNF-α level after CS and 
simulated EVLP/R (Figure 22B), indicating that the release of TNF-α is induced during the 
rewarming phase of the macrophages. 
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Figure 22: CysC-Alb and CA-074 reduces TNF-α in an in vitro model of CS and simulated 
EVLP/R. Macrophages were treated with Alb, CysC-Alb or CA-074 (CatB inhibitor) in 
Perfadex during 18 h CS, or 18 h CS + 6 h simulated EVLP/R, followed by the 
measurement of TNF-α in the Perfadex samples by ELISA. (A) Detection of TNF-α in 
Perfadex samples containing Alb, CysC-Alb or CA-074. (B) Comparison of TNF-alpha levels 
in Perfadex containing CysC-Alb or Alb after 18 h CS alone and 18 h CS following 6 h 
simulated EVLP/R. Data are shown as means ± SEM of 5 replicates per group and a two-
tailed Mann-Whitney test was used for statistical analysis. *p ≤ 0.05, **p ≤ 0.01 
 
3.1.6.4 CysC-Alb has no effect on TNF-α expression 
To examine the modulatory effect of CysC-Alb on cytokine expression during CS and 
EVLP/R, CS and EVLP/R at 37°C was simulated in macrophages. As illustrated in Figure 23, 
the gene expression of TNF-α (Figure 23B), IL-1α (Figure 23C), and IL-1β (Figure 23D) 
were not altered in the CysC-Alb group compared to the Alb control group. CysC-Alb 
significantly up-regulated the mRNA expression of anti-inflammatory IL-10 relative to the 
control (Figure 23A). However, it is noteworthy that the relative expression of IL-10 is 
very low in both treatment groups and thus should not been taken into consideration.   
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Figure 23: CysC-Alb does not affect TNF-α gene expression. Macrophages were treated 
with Perfadex containing Alb or CysC-Alb during 18 h of CS and 6 h simulated EVLP/R. 
mRNA expression levels of IL-10, TNF-α, Il-1α and IL-1β were measured by quantitative 
real time PCR. Hypoxanthine-guanine-phosphoribosyltransferase (HPRT) was used as 
reference gene for normalization. Data are shown as mean ± SEM of 4 replicates and a 
two-tailed Mann-Whitney test was used for statistical analysis. *p ≤ 0.05 
 
3.1.6.5 CysC-Alb inhibits CatB-induced activation of TACE 
TNF-α release is mainly mediated by shedding of the membrane-bound TNF-α by TNF-α 
converting enzyme (TACE). As we demonstrated that the addition of CysC-Alb to 
Perfadex diminished TNF-α release as a response of CatB inhibition in our in vitro model 
of CS and simulated EVLP/R, we analyzed if CatB is involved in the regulation of TACE 
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activity in whole macrophage lysates. Consistent with the reduction in TNF-α, CysC-Alb 
significantly inhibited TACE activity compared to Alb (Figure 24A), implicating that active 
CatB regulates TACE activity and thereby induces TNF-α shedding. Moreover TACE 
activity of CysC-Alb treated macrophages correlated with the activity of TACE in 
macrophages treated with specific TACE/ADAM10 inhibitors (TACE/ADAM10 inhibitor: 
GW280264, Figure 22A). GW treatment during CS and simulated EVLP/R also significantly 
blocked TNF-α release from macrophages in Perfadex (Figure 24B).  
 
Figure 24: CatB is involved in the regulation of TACE. Macrophages were treated with 
Perfadex containing Alb, CysC-Alb or the TACE/ADAM10 inhibitor GW280264 during 18 h 
of CS and 6 h simulated EVLP/R. (A) TACE activity was detected in whole macrophage 
lysates using SensoLyte® 520 TACE (α-Secretase) Activity Assay Kit. (B) Perfadex samples 
were collected for detection of TNF-α by ELISA assay. Data are shown as mean ± SEM of 4 
replicates and a two-tailed Mann-Whitney test was used for statistical analysis. *p ≤ 0.05 
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3.2 CatC inhibition in LTx - Results 
In order to evaluate the potential beneficial effect of ICatC pretreatment in mice 
recipients we have chosen a murine experimental model of orthotopic LTx illustrated in 
Figure 25. From a previous study with rats we knew that 10 days of ICatC treatment 
would be sufficient to effectively reduce NSP activities in circulating neutrophils and two 
doses per day are needed because of the short circulation half-life of ICatC. The outcome 
of ICatC pretreatment of the two treatment groups (ICatC and vehicle) were compared 
by analyzing different parameters 4 h after reperfusion of the transplanted left lung lobe. 
The orthotopic LTx was performed by Natalia Smirnova (iLBD, Helmholtz Zentrum 
München) and the EVLP by Carmela Morrone (iLBD, Helmholtz Zentrum München). 
 
Figure 25: ICatC premedication and lung transplantation procedure. Experimental 
outline of subcutaneously injections of 100 µl ICatC (1.25 mg/ml) in C57BL/6J recipient 
mice, donor lung graft storage in Perfadex during cold ischemia (18 h, 4°C) followed by 
graft transplantation and reperfusion (4 h, 37°C).Specimen were collected 4 h after 
reperfusion and analyzed. 
 
3.2.1 CatC inhibition leads to reduced NSP activity in the bone marrow 
To investigate, if preventive ICatC treatment of recipient mice eliminated the conversion 
of serine-protease zymogens to their active forms during biosynthesis, we measured the 
relative PR3 and NE activities in lysates of purified BM-derived neutrophils using 
optimized FRET substrates for murine serine proteases. Cleavage of the murine PR3 
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substrate, TAMRA-GVRRVVQYQD-dap-(CF) and the substrate ABZ-GAVVASELR-Y-(NO2)-D 
for both, murine NE and PR3 was determined in PMN lysates of ICatC and Veh treated 
mice. PMN lysates of ICatC mice revealed significantly less enzymatic activity of (Figure 
26A) PR3 and (Figure 26B) NE compared to vehicle (Veh) treated mice. As negative 
control, PMN lysates of PR3/NE double knockout (PR3/NE -/-) mice were used. The 
obtained fluorescence signal in these cells reflects the unspecific substrate cleavage by 
the lysates. Consequently, the remaining PR3 activities in ICatC treated mice are due to 
unspecific cleavage of the substrate. Our results indicate that PR3 and NE activities are 
almost completely eliminated in BM-derived neutrophils.  
 
Figure 26: ICatC treatment reduces NSP activity in the bone marrow. Neutrophils were 
isolated from the BM 4 h after reperfusion. To determine NSP activity after 10 days ICatC 
treatment neutrophil lysates were tested by a FRET-based activity assay. (A) PR3 activity 
was measured with the FRET-substrate TAMRA-GVRRVVQVQD-Dap-(CF) and (B) NE 
activity with the FRET-substrate Abz-GAVVASELR-Y-(NO2)-D. Neutrophil lysate from 
PR3/NE -/- mice were used as negative control. The initial reaction velocity (V0) was 
obtained by determining the slope of the linear portion of the data plot. Values are 
represented as means ±SEM of 3-4 mice per group and compared with a Mann-Whitney 
test (*p ≤ 0.05). The y-axis shows the fluorescence in relative fluorescence units (RFU). 
 
Next, we performed WB analysis with PMN protein lysates to examine whether the 
reduced enzymatic activities after ICatC treatment correlate with the protein content of 
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PR3 and NE. Densitometry and statistical evaluation revealed no differences of PR3 and 
NE immunoreactive proteins in PMN lysates of ICatC and vehicle treated mice (Figure 
27A,B).  
 
Figure 27: Western blot analysis for PR3 and NE in PMN lysates. 15 µg of PMN lysates of 
ICatC and Veh treated mice were loaded onto a 12% SDS gel, followed by immunoblot 
analysis of PR3 and NE. (A) Representative Western blot images and (B) densitometry 
analysis of PMN lysates for PR3 and NE using specific polyclonal PR3 (1:1000) and 
monoclonal NE (1:1000) antibodies. Immunodetection of β-actin served as loading 
control. Values are represented as means ±SEM of 4 mice per group. 
 
3.2.2 ICatC pretreatment improves PGD and reduces the inflammatory response  
4 h after reperfusion mice were euthanized and the air and blood flow of the non-
transplanted right lung was stopped by clamping the right bronchus to measure the 
partial oxygen pressure (pO2) in the left heart ventricle. Decreased pO2 values indicate 
graft dysfunctions after prolonged cold ischemic storage. Pretreatment with ICatC 
resulted in an almost 20% higher blood oxygenation (Figure 28) in the transplanted left 
lung. 
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Figure 28: ICatC pretreatment improves primary graft function. Recipient C57BL/6J mice 
were euthanized 4 h after reperfusion and the partial oxygen pressure (pO2) of the 
oxygenated blood in the left heart ventricle was measured after clamping the right 
bronchus for 5 min. Data is presented as group means ±SEM of 4 and compared with a 
Mann-Whitney test (*p ≤ 0.05). 
 
After the pO2 mesurements, different specimen were collected to analyse the impact of 
ICatC treatment on graft protection. As envisoned, we found a highly protective effect of 
ICatC against the inflammatory response after LTx. Immunohistochemical staining of lung 
graft tissue by the neutrophil-specific antibody Ly-6G were performed to compare 
neutrophil infiltration in the lung tissue after reperfusion (Figure 29A). Analytical 
evaluation of images revealed no differences in the number of lung infiltrating 
neutrophils in both groups (Figure 29B). BAL neutrophil counts for the two different 
treatment groups showed a clearly decreased amount of neutrophils in ICatC treated 
mice compared to Veh treated mice (Figure 29C), indicating the preservation of the 
capillary barrier after ICatC treatment. Furthermore, we looked into changes in the 
proinflammatory cytokine levels of IL-1β, Il-6, Il-8, Il-12, Il-17, TNFα and INFγ, and found a 
significant reduction in IL-6 after ICatC treatment (Figure 29D). 
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Figure 29: ICatC pretreatment improved lung graft quality and reduced inflammatory 
response. The outcomes of ICatC and vehicle treatment were compared after sacrificing 
the mice 4 h after LTx. (A) Immunohistochemical staining and (B) quantification of 
neutrophils in the transplanted left lung from 10 randomly chosen visual fields. (C) 
Bronchoalveolar lavage neutrophil counts for ICatC and vehicle treated animals. (D) BAL 
fluid was obtained and analyzed for proinflammatory IL-6 for the two different treatment 
groups. Scale bar = 100 µm. Magnification is indicated as 20x. Data is presented as group 
means ±SEM. n = 4-5 mice per group. *p ≤ 0.05 (Mann-Whitney test), **p ≤ 0.01 
(independent t-test) 
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3.2.3 Presence of NSP positive neutrophils in the lung 
As Papillon-Lefevre patients, which are characterized by a loss of function mutation in 
the CatC gene (CTST), do not only show a defect in zymogen processing, but also 
eliminate NSP zymogens completely, we hypothesized that this is also the fate in mice. 
To test the hypothesis in our experimental model after pharmacological CatC inhibition, 
we stained paraffin lung sections with Ly-6G and NE antibodies for co-localization 
detection of neutrophils and NE. All neutrophils were positive for NE revealing the 
presence of the NE protein in the lung (Figure 30).  
 
Figure 30: Appearance of NE positive neutrophils in lung tissue after ICatC treatment 
and LTx. Paraffin-embedded tissue sections of the transplanted left lung of ICatC and 
vehicle treated mice were fluorescently stained with both a monoclonal Ly-6G - (clone 
1A8, 1:400) and a polyclonal NE specific (1:1000) antibody for colocalization analysis of 
neutrophils and NE. Sections shown are representative images of 4 mice per group. 
Magnification is indicated as 20x, scale bars = 50 µm. 
 
Additionally, we found no differences in PR3 and NE protein levels after ICatC treatment 
when whole lung tissue was analyzed by semi-quantitative WB and densitometry (Figure 
31A/B). These findings were supported by quantitative ELISA measurements of NE, which 
did not show a significant difference between ICatC and Veh treated mice (Figure 31C). 
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Moreover, the graph reveals the differences in NE protein in whole lung tissue and PMN 
lysate (Figure 31C). Whole lung tissue and PMN lysate from PR3/NE -/- mice was used as 
negative control. Since the NE antibody used for immunohistochemistry and WB analysis 
is not able to distinguish between active and inactive (zymogen) NE we wanted to clarify 
whether the detected PR3 protein in whole lung lysates was enzymatically active. Alpha-
1-antitrypsin (AAT) antibody was used to detect the formation of an irreversible complex 
with active PR3/NE, which is expected to appear as a 77 kDa band after SDS PAGE and 
Western blotting. Alpha-1-antitrypsin (AAT) is only able to form a complex with mature 
PR3/NE, not with the inactive pro-PR3/NE. The results reveal that PR3/NE is not 
proteolytically active after ICatC treatment as indicated by the lack of 77kDa complex 
formation in comparison to vehicle treatment (Figure 31D). 
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Figure 31: PR3 and NE zymogens are present in lung tissue after ICatC pretreatment. 
Whole lung tissue lysate of the transplanted left lung lobe of both groups were analyzed 
by Western blot and ELISA. (A) Representative Western blots and (B) densitometry 
determination of whole lung lysate PR3 and NE in ICatC treated mice compared to 
vehicle treated mice. (C) Quantitative determination of NE protein in whole lung tissue 
and in PMN lysates from vehicle-, ICatC-treated and PR3/NE-/- mice. (D) In order to 
determine if the detectable PR3 and NE are enzymatically active, PR3, AAT and PR3/AAT 
complexes were simultaneously detected by immunoblotting. Immunodetection of β-
actin served as loading control.  
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4. Discussion 
4.1 CysC-Alb in LTx – Discussion 
Donor lungs transported and stored for more than 6 h are not accepted for 
transplantation because of a high risk of postsurgical complications and transplant 
dysfunction. The short storage period limits the availability of lung grafts for 
transplantation. Extended storage times increase the extent of metabolic and structural 
changes in the transplant and as a consequence the severity of the early inflammatory 
response in the transplant after reperfusion.  
In this study, we investigated the role of CatB released from lysosomes during extended 
CS of 18 h and 2 h EVLP, and its impact on early graft dysfunction after 4 h LTx. To this 
end, we developed different variants of the endogenous cysteine protease inhibitor, 
CysC, and as a result were able to show that it is protected from lysosomal degradation 
and can be utilized for imaging applications in vitro. We explored its clinical potential in 
organ preservation during CS and EVLP in graft protection from I/R injury after LTx using 
a clinically relevant mouse model and an in vitro model of CS and simulated EVLP/R. Our 
results demonstrate that CysC-Alb protects lung cells from apoptosis and improves early 
graft function immediately after reperfusion of the transplanted lung. Moreover, our 
findings indicate that TNF-α release during simulated CS and EVLP/R is a consequence of 
CatB induced TACE activation. 
4.1.1 Development of a highly potent cysteine protease inhibitor 
Biopharmaceuticals generally face the problem of rapid clearance. In order to create a 
more efficient inhibitor for therapeutic applications, the endogenous cysteine protease 
inhibitor, CysC was covalently attached to the N-terminus of Alb by gene fusion. Due to 
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the unique recycling mechanism of Alb via the FcRn, we developed a novel inhibitor with 
anticipated prolonged circulatory half-life and a high inhibitory activity against CatS and 
CatB. The fusion of small therapeutic molecules, such as α and β interferon (60, 61), 
insulin (62) and granulocyte stimulating factor (52), to Alb has already been intensively 
explored and all reports documented improved pharmacokinetics compared to the non-
fused analogues. The first Alb fusion therapeutic was approved for the treatment of 
diabetes mellitus type II in 2014 (63).   
Initially, the authentic sequence of mouse CysC was used for the production of the Alb 
fusion inhibitor. However, N-terminal protein sequencing revealed three different 
protein variants, with only one having a full length N-terminus. The most crucial part for 
the interaction of CysC with cysteine proteases are the three N-terminal amino residues 
before the first glycine, which are highly conserved (64). Since CysC-Alb is able to enter 
endosomal compartments due to its binding affinity to FcRn, we suggest that CysC-Alb 
was posttranslational processed by endosomal endo-peptidases and -proteases. Hence, 
we have chosen to exchange the mouse N-terminal sequence by the N-terminal 
sequence of chicken CysC which is not prone to posttranslational processing. CysC is a 
monomeric protein with two conserved disulfide bridges (Cys73-Cys83 and Cys97-
Cys117), but when crystallized it forms domain-swapped homo-dimers. Once formed, 
CysC dimers completely lose their inhibitory activity against cysteine proteases. In order 
to avoid dimer formation, a monomeric stable mouse CysC was designed by introducing 
an engineered third disulfide bond (Cys47-Cys69). According to Kolodziejczyk et al. this 
variant of human CysC is significantly less susceptible to dimerization and its inhibition of 
papain is unaltered (65).  
In the present pre-clinical LTx study, CysC alone would be rapidly cleared metabolically. 
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Hence, we used the newly invented efficient inhibitor with enhanced tissue und cell 
penetration and where able to detect high levels of CysC in lung tissue perfused with 
CysC-Alb during CS and EVLP. Other specific small molecule inhibitors of lysosomal 
cysteine proteases would possibly have a similar effect; however, low toxicity and site 
specific actions of therapeutics are crucial for their safety. The organ preservation 
procedure presented in this study would be technically feasible in a clinical trial with no 
intolerance risk for the patients due to the fact that CysC and Alb are endogenous 
proteins and are tolerated as self-antigens.  
4.1.2 Effect of CysC-Alb on lung graft quality 
The results of our preclinical study strongly support our hypothesis that inhibition of 
extracellular lysosomal cysteine proteases by CysC-Alb during CS and EVLP is suited to 
protect lung cells from apoptosis inducing signals and could improve early lung transplant 
function in patients. We assume that CysC-Alb of the preservation solution diffused into 
the perivascular and interstitial space of the lung graft during CS and EVLP and was 
therefore optimally positioned to protect the graft against extracellular cysteine 
proteases released from lysosomes. EVLP complies with existent ethical standards in 
clinical research and was therefore included in our setting.  
The inhibitory effect of CysC-Alb on cysteine protease activity appears to represent a 
major mechanism of lung transplant protection in this pre-clinical model. Our results 
indicate that the inhibitory activity of CysC-Alb attenuated apoptotic cell death of AT2 
cells and macrophages in the lung transplant which usually occurs during CS, EVLP and R. 
Apoptosis has been described to contribute to I/R injury in various models of human and 
mouse I/R injury, including lung models. Ischemic storage is associated with necrosis, 
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whereas apoptosis dominates during early reperfusion. In a human LTx study lungs had 
about 30% of their cells undergoing apoptosis 2 h after reperfusion (66). Similar results 
were obtained experimentally after 6 and 12 h ischemic storage, however longer storage 
periods were associated with predominantly necrotic cells in lung tissue of rats (67).  
Whether apoptotic cell death is harmful for organ function remains controversial. Fischer 
et al. have demonstrated a correlation between necrosis and transplanted lung function, 
but apoptosis did not correlate with lung function (67). In contrast, other authors stated 
that injections of anti-apoptotic agents before reperfusion reduced I/R injury of the 
kidney and heart in mouse models after warm ischemia (68, 69). We have observed 
improved lung function of transplants preserved in CysC-Alb 4 h after reperfusion and 
could show the reduction of AT2 apoptosis, suggesting a link between AT2 survival and 
lung function after transplantation. AT2 cells are mostly found at the alveolar-capillary 
barrier, where they play important roles for the normal pulmonary function: Production 
of pulmonary surfactant, transepithelial movement of water, and regeneration of the 
alveolar epithelium following lung injury (40).  
Ischemic CS initiates the activation of resident macrophages, which release 
proinflammatory cytokines and mediate I/R injury during reperfusion. TNF-α is one of 
them and is a key player in the induction of the extrinsic apoptotic pathway. Moreover, 
TNF-α has been described to activate nuclear factor κB (NFκB), which is known to be 
involved in the apoptosis signaling pathway (70). As the supplementation of CysC-Alb to 
Perfadex during CS and EVLP reduced both, TNF-α and apoptotic cells 4 h after LTx, it 
seems likely that TNF-α functions as a mediator of the apoptotic cascade in our setting. 
Additionally, there is evidence that TNF-α is implicated in the early phase of organ 
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reperfusion during which it was shown to induce organ damage (71-73). TNF-α blockade 
had a protective effect against organ injury after intestinal I/R injury (74).  
With the development of CysC-Alb we intended to target extracellular cysteine proteases 
either actively released from lysosomes or leaked from permeable lysosomes. Due to the 
fusion to Alb, CysC might also act intracellulary while it is bound to FcRn in early 
endosomes. Apart from its extracellular function, CysC has been shown to inhibit human 
coronavirus replication (75) and CatB and legumain activity in cancer cells (76, 77), 
indicating that CysC functions intracellularly too. Using CysC-Alb-Ruby, we showed for the 
first time by immunofluorescence imaging that CysC-Alb is internalized by macrophages 
via FcRn binding. Despite these possibilities our results let us assume that the effect of 
CysC-Alb on TNF-α release and apoptosis is primarily mediated via an extracellular 
mechanism.  
4.1.3 CysC-Alb protects lung cells from CatB mediated damage  
To clarify the therapeutic mechanism of CysC-Alb in immediate lung graft protection, we 
tested the anti-apoptotic and anti-inflammatory effects of CysC-Alb in a cell culture 
model that simulates features of lung preservation and reperfusion at body 
temperatures. 18 h of CS and 6 h EVLP/R simulation at 37°C resulted in reduced cell 
viability, a result similar to what was observed in another cell model of simulated I/R 
injury (78), as well as in rat lung transplant studies in which significant cell death was 
found after 18 h of ischemic storage (67, 78). CysC-Alb was not able to reduce cell death 
in our in vitro model of CS and EVLP/R simulation, as shown by analyzing cleaved caspase 
3. These findings indicate that primary cell death caused by the harsh physical conditions, 
such as CS and the incubation solution, cannot be prevented by CysC-Alb. Nevertheless 
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CysC-Alb significantly inhibited CatB activity in Perfadex samples, which were released 
from lysosomes of dying or stored cells. Consequently, we assume that CysC-Alb has an 
effect on the secondary damage of lung cells caused by extracellular CatB, which cannot 
be demonstrated in our in vitro model of CS and simulated EVLP/R. 
The greatest lung tissue damage is thought to be caused by the return of blood 
components at body temperature after transplantation (79). This is supported by our 
findings that cell viability and CatB release is significant increased after CS followed by 
simulated EVLP/R at 37°C compared to CS preservation alone. 
4.1.4 CatB is involved in the regulation of TACE 
The metalloprotease TACE performs ectodomain shedding of various transmembrane 
proteins, most of which are regulators involved in inflammatory processes, including 
TNF-α, both its receptors (TNFRI,TNFRII), IL-6R and ligands of the epithelial growth factor 
receptor (EGFR) (80-82). Hence, TACE activity is a key player in controling inflammatory 
signaling pathways (81, 83). TACE activates TNF-α signaling by proteolytic cleavage of 
membrane-bound pro-TNF-α thereby releasing active TNF-α from the cell surface (80).  
In this study, we were able to reduce TNF-α release in vivo during EVLP as well as in our 
in vitro model of I/R injury by CysC-Alb treatment. CysC has been shown to reduce TNF-α 
mRNA expression and subsequently release of TNF-α in LPS activated monocytes by 
downregulating phosphorylation of the ERK1/2 pathway (84). By contrast, in our study 
gene expression levels of TNF-α were not affected pointing to an ERK1/2 signaling 
pathway independent mechanism of TNF-α release. Therefore, we examined whether 
CatB inhibition might have a direct effect on TACE activity.  We analyzed the activity of 
TACE on the surface of macrophages after CS and EVLP/R simulation at 37°C. TACE 
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activity was found to be lower on the cell membrane after CysC-Alb treatment. The 
possibility of a direct effect of CysC-Alb on TACE activity was excluded by confirming the 
results with a specific CatB inhibitor. 
To date, the regulatory mechanisms leading to TACE maturation and subsequent 
activation are not fully elucidated. Catalytic active TACE is synthesized as inactive 
proenzyme, in which the N-terminal pro-domain acts as autoinhibitor preventing the 
enzyme from inappropriate premature processing of substrates (85). One of the most 
important posttranslational modifications is the removal of the pro-domain in the Golgi 
that occurs at two different sites before active TACE is trafficked to the cell surface. One 
site, namely the downstream site, is located between the pro-domain and the catalytic 
domain and contains a proprotein convertase (PC) consensus cleavage site (86). The 
secondary cleavage site to this perequiste cleavage is embedded within the N-terminal 
pro-domain (referred to as upstream site) (87). Furin like proteases, members of the PC 
family, have been demonstrated to be involved in the activation of metalloproteases in 
several studies. For instance, mutations in the furin cleavage site of the downstream site 
of metalloproteases ADAM10, ADAM12 and ADAM19 prevented the removal of the pro-
domain and as a consequence kept the enzyme inactive (88, 89). According to Wong and 
colleagues only furin like proteases are implicated in the processing of the upstream site 
of TACE, whereas the downstream site cleavage can be processed by other proteases or 
could be autocatalytically nicked (87). By contrast, myeloid cells were shown to have 
TACE shedding activity despite blocking of all PCs (90). This indicates that the role of furin 
in processing of TACE is complex and still not understood in detail. Another 
posttranscriptional modification, which has been argued to be hallmark of TACE activity, 
is the phosphorylation of the cytoplasmic domain of TACE by mitogen-activated protein 
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kinases (MAPK) and polo-like kinase2 (PLK2) (91, 92). Furthermore it is speculated that 
phosphatidylserine is required to be exposed on the cell surface to bring TACE into 
position for shedding its targets (93). Activation of TACE seems to depend on the 
availability of co-factors influencing TACE biology and might be cell type specific. 
Recently,  iRhom has been described as one of these cofactors promoting the trafficking 
from the ER to the Golgi and after the release of the pro-domain the trafficking to the 
plasma membrane (94). We suggest that CatB is involved in the activation of TACE as a 
cofactor under pathological conditions such as I/R injury. A possible scenario would be 
the processing of an adjacent cleavage site to the downstream PC site of the prodomain. 
Whether the CatB dependent TACE regulation occurs during TACE maturation, export or 
on the cell surface and by which mechanism remains to be elucidated in the future.  
4.1.5 Limitations 
Several limitations to the EVLP and the LTx procedure performed here needs to be 
addressed. The EVLP circuit design in this study is “open” rather than “closed” as usually 
used in EVLP protocols in clinics. We envisaged a favorable effect by replacing the 
perfusate solution during EVLP, and hereby removing proinflammatory cytokines and 
neutrophils that could concentrate in the lung in a closed circuit. The potential benefit of 
this approach has been stated before in a murine and a human EVLP study (95, 96). 
Parameters that are evaluated as standard in human EVLP protocols, such as pulmonary 
vascular resistance and airway pressures could not be monitored, as it is technically not 
feasible in our murine EVLP system. In comparison to human allogenic lung grafts, the 
transplanted lungs were taken from young, healthy isogenic donors. The unavoidable 
blood loss in the recipient mice during the microsurgical procedure was not 
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compensated by blood transfusions. Hence, the hemodynamic and circulatory status of 
the transplanted mice during the post-surgical phase was not ideal. Despite these 
challenges, which affected all experimental groups, we believe that our results are a 
promising basis for future studies. Another important point that should be mentioned is 
that we only examined the impact of CatB inhibition by CysC-Alb in our experimental 
setting. However, CysC-Alb also inhibits lysosomal CatS and CatL; hence there is a 
possibility that our results are the consequence of multiple cysteine protease inhibition, 
and not only CatB inhibition alone.  
 
In summary, by analyzing the protective effect of CysC-Alb during lung transplant 
preservation, we have demonstrated that CysC-Alb improves lung function and 
diminishes apoptotic cell death after LTx. We propose that CatB released from lysosomes 
of macrophages during CS and EVLP/R mediates TACE activation on the cell surface, 
which induces TNF-α secretion. TNF-α binds to death receptors on other lung cells and 
induces the extrinsic apoptotic signaling cascade leading to apoptosis (Figure 23). CysC-
Alb inhibited extracellular CatB in our experimental set-up and thereby prevented 
shedding of membrane bound TNF-α, and the subsequent induction of AT2 and 
macrophage apoptosis. By using CysC-Alb containing perfadex we were able to prevent 
the secondary damage of lung cells caused by lysosomal CatB. 
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Figure 32: Proposed mechanism of apoptosis induction during CS and EVLP/R. In the 
course of CS and EVLP/R, cathepsins including CatB are released from lysosomes of dying 
or reversibly stressed cells. Extracellular CatB activates TACE on these and other cells. As 
a consequence, TNF-α is shedded from the cell membrane and binds to death receptors 
on other cells, inducing the intrinsic apoptotic pathway by cleavage of pro-caspase 8 and 
pro-caspase 3, 7. 
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4.2 CatC inhibition in LTx - Discussion 
Neutrophils are usually the first leukocytes to infiltate transplanted organs during 
reperfusion and are well recognized to be critical mediators for I/R injury (135). 
Therefore, they are a great risk factor for the development of PGD and chronic allograft 
rejection. Most work on neutrophils during I/R has focused on their destructive 
properties, that causes tissue damage by the release of oxidative effectors and NSPs 
(116, 117, 136). In this preclinical study, we demonstrate that NSP mediated 
inflammation and dysfunction of the lung transplant can be mitigated by the prevention 
of their biosythesis in the BM by CatC inhibition several days before LTx. We revealed 
that the pharmacological inhibition of CatC did not only reduce NSP maturation in the 
bone marow of mice recipients, but also had a protective effect on post-operative lung 
function and reduced the inflammatory response after reperfusion. 
4.2.1 Effects of eliminated NSP activity on LTx outcome 
NE and PR3 are both destructive enzymes with a wide range of substrates including 
various components of the extracellular matrix. In addition to matrix degradation, NE 
influences cell signaling by cleavage of receptors, cytokines and adhesion molecules 
(102). The exact role of NE and PR3 in I/R injury still remains poorly defined at the 
molecular biochemical level in vivo and vitro. Nevertheless, clear evidence for the 
involvement of NSPs in I/R injury and PGD development following organ transplantation 
has been provided in previous pre-clinical studies.  Silvestat, a synthetic NE inhibitor, was 
succesfully used to suppress neutrophil activation and secretion of proinflammtory 
mediators after I/R injury in rodents and in an ex vivo perfusion model in pigs. In 
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addition, Silvestat increased the survival rate after I/R injury caused by supravisceral 
aortic clamping in rats (116, 117, 137). We could confirm the benefical effect of reduced 
NSP activity by showing decreased alveolar permeability, improved lung function and 
reduced inflammatrory mediators as a result of CatC inhibition.  
Furthermore, in the present study we demonstrated significant decreased IL-6 levels in 
BALF after ICatC treatment of the recipient shortly after reperfusion of the transplanted 
lung. IL-6 is an important mediator of the acute phase response, but also stimulates 
inflammatory and auto-immune proccesses in many diseases by multiple pathways. As 
such, IL-6 has been implicated in the pathophysiology of PGD. In a large cohort of 336 
patients, early post-transplant BALF IL-6 was associated with an increased prevalance of 
PGD (138). Indeed, it was revealed in another small patients cohort that BALF IL-6 levels 
were increased in patients with PGD compared to those without PGD development (139). 
Furthermore, gene set enrichment and gene expression analyses already identified IL-6 
as a key mediator in the inflammatory pathway of PGD development in patients and a rat 
I/R injury model (140, 141). Similaly to our study, Iskender et al. used  AAT, a proteinase 
inhibitor with anti-inflammatory properties in a pig LTx study to reduce the inflammatory 
response related to IR injury. All observed cytokines were lower in the AAT treatment 
group with IL-6 being significantlly reduced (142). Beyond its proteolytic function, NE 
further enhances inflammatory responses probably via an induction of IL-6 and IL-8 
release.  
4.2.2 CatC inhibition severly reduces NSP activity in the BM and lung 
Activation of NSP zymogens requires the cleavage after a glutamic acid residue at their N-
terminus by CatC (143). In the absence of CatC activity, zymogens are sythesized in 
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neutrophil precursors in the BM, but are differently eliminated during neutrophil 
maturation in mice and men. As reported for mice deficient in the CatC gene, CatG was 
undetectable in BM-derived PMN lysates, while NE bands were still present as shown by 
WB. NE activity in PMN lysates, however, were severely reduced and equivalent with the 
background activity in NE knockout mice (107). These previous findings from mice with 
genetic CatC deficiency are in line with our data in ICatC treated mice, revealing 
immunoreactive PR3 and NE in lysates from BM-derived PMNs. After LTx, PR3 and NE 
were detected by immunofluorecence in transplant infiltrating neutrophils in ICatC and 
Veh treated recipient mice. Moreover, their protein levels were verified by WB in whole 
lung tissue of both groups. Adding an excess of AAT, a protease activity dependent NSP 
inhibitor, we investigated whether or not the immunoreactive NSPs in whole lung tissue 
are zymogens. We found inactive zymogens of PR3 in ICatC treated recipients, but active 
PR3 in Veh treated recipients. Covalent complexes between NSPs and AAT are 
susceptible to degradation by other proteases, which most likely explains the additional 
bands of smaller size in the lung lysates of Veh treated mice. Our observations indicate 
that sorting of NE/PR3 to azurophil granules occurs normally in the presence of the 
prodipeptide in mice. The fact that CatG levels were found to be reduced in a previous 
study, suggest that NSPs may not be sorted in an identical manner. In the absence of 
CatC, CatG zymogens can be missorted into a different class of granules (144), which 
potentially targets them for degradation.  
Biallelic missense mutations with loss of CatC and its activity in PLS patients are 
associated with a concomitant reduction in the amounts and activities of NSPs in 
circulating mature neutrophils in PLS patients. Zymogens, however, are normally 
synthesized and sorted in PLS promyelocytes and disappear during subsequent stages of 
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neutrophil differentiation probably because of intracellular degradation (145). These 
findings were in agreement with observations in macaques after prolonged 
pharmacological inhibition of CatC. In contrast, our data show the presence of zymogens 
in mature neutrophils in murine lung tissue. The difference between primates and 
rodents could be attributed to differences in the number of neutrophils and their serine 
protease zymogen levels or by an increased susceptibility of zymogens to intracellular 
degradation in humans.  
4.2.3 Clinical potential of our translational approach 
Despite conservative clinical approaches of the lung graft, about 25% of lung transplant 
recipients still develop PGD. Hence, ameliorating treatment options for LTx recipients is 
crucial to improve LTx outcome. In two phase 1 studies of healthy volunteers, Cat C 
inhibition was well tolerated with only minor skin desquamation as side effects, but 
these were not considered to prevent further clinical studies (127, 128). Long-term 
administration of a CatC inhibitor developed by AstraZeneca is currently assessed in 
bronchiectasis patients over a 24 week treatment period (ClinicalTrials.giv Identifier: 
NCT03218917). Solid evidence for a save and ethically acceptable application of CatC 
inhibitors have been given; hence they may also be considered as a treatment option for 
patients on the LTx waiting list. As patients on the LTx waiting list usually suffer from end-
stage pulmonary diseases and are therefore closely or stationarily monitored with 
intensive medical care, it would be feasible to treat them long term during their waiting 
time for a lung transplant. With the pre-operative ICatC treatment of the recipient it 
would be possible to suppress the inflammatory response mediated by recruited and 
activated neutrophils, and the subsequent local NSP release. Our results indicate that 10 
days of CatC inhibition are sufficient to reduce NSP activities completely in mice.  Looking 
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at neutrophil maturation kinetics in humans, treatment with a CatC inhibitor will require 
21 days of administration to be efficacious in humans (146, 147). This is not a limiting 
factor as transplantation patients usually face more than 15 days on the LTx waiting list. 
Furthermore, according to this study and a previous one in primates, CatC inhibition does 
not compromise neutrophil recruitment to the site of inflammation, indicating that the 
diverse and highly redundant neutrophil defense mechanisms are not impaired by CatC 
inhibition in general. 
4.2.4 Limitations 
As the investigational novel drug INS1007 was not available to us for transplantation 
studies in mice, a functionally similar CatC inhibitor, XPZ-01, was assessed by 
subcutaneous administration of two daily doses in this pilot study. Due to the highly 
challenging transplantation procedure in mice, we studied only the outcome of PGD 4 h 
after LTx and evaluated the effect of only one dose of ICatC.  Many data which are 
routinely monitored in the clinics cannot be recorded in a small animal transplantation 
model. Therefore, we have not measured blood pH, carbon dioxide in the left pulmonary 
artery or right ventricle and graft compliance 4 hours LTx.  However, our positive results 
encourage for future studies assessing beneficial effects after longer treatment periods, 
different doses and longer observation post LTx. 
In conclusion, nearly complete inhibition of NE and PR3 activities was demonstrated with 
a reversible CatC inhibitor in an experimental murine LTx model. With this anti-
proteolytic shield early LTx outcome of transplanted mice has been improved. We 
anticipate that preoperative treatment with CatC inhibitors in humans is a safe and 
adjustable treatment option for LTx candidates. In view of the promising phase I trials, 
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CatC inhibitors can be rapidly translated into clinics. CatC inhibitors alone or in 
combination with improved organ preservation procedures represent a novel drug class 
for the prevention of early post-operative complications and the development of PDG 
post LTx. 
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µl   Microliter 
aa   Amino acid 
AAT   α-1-antitrypsin proteinase inhibitor 
Alb   Albumin 
APS   Ammonium persulfate 
Asp   Aspartic acid 
BAL   Bronchoalveolar lavage 
BALF   Bronchoalveolar lavage fluid 
BM   Bone marrow 
BOS   Bronchiolitis obliterans syndrome 
bp   Base pair 
Cat. No.  Catalog number 
CatB   Cathepsin B 
CatC   Cathepsin C 
CatG   Cathepsin G 
CatH   Cathepsin H 
CatL   Cathepsin L 
CatS   Cathepsin S 
COPD   Chronic obstructive pulmonary disease 
CS    Cold storage 
CysC   Cystatin C 
CytC   Cytochrome C 
Da   Dalton 
ddH2O   Double destilled water  
DNA   Deoxyribonucleic acid 
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DPPI   Dipeptidypeptidase I 
EGFR    Epithelial growth factor receptor 
ELISA   Enzyme-linked immunosorbent assay 
Endo H   Endo-ß-N-acetylglucosaminidase H 
EVLP   Ex vivo lung perfusion 
FcRn   neonatal Fc receptor 
FRET   Förster/Fluorescence resonance energy transfer 
gCysC    chicken Cystatin C 
HDL   High density lipoprotein 
HE    Hematoxylin Eosin 
HEK   Human embryonic kidney cell line 
hFcRn    Human neonatal Fc receptor 
His   Histidine 
HRP   Horseradish peroxidase 
IL-6    Interleukin 6 
i. p.   Intra peritoneal 
IPF    Idiopathic pulmonary fibrosis  
I/R   Ischemia reperfusion 
LDL   Low density lipoprotein 
LPS   Lipopolysaccaride 
LTx   Lung transplantation 
mAb   Monoclonal antibody 
MHC-I   Major histocompatibility class I 
mCysC   Chicken Cystatin C 
mFcRn   Mouse neonatal Fc receptor 
min   Minutes 
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mRNA   Messenger ribonucleic acid 
NE   Neutrophil elastase 
NEB   New England Biolabs 
NFκB    nuclear factor κB 
NSPs   Neutrophil serine protease 
NSP4   Neutrophil serine protease 4 
OD   Optic density 
on   over night 
PBMC   Peripheral blood mononuclear cell 
PBS   Phosphate buffered saline 
PC    Proprotein convertase  
PEI   Polyethyleneimine 
PGD   Primary graft dysfunction 
pI   Isoelectric point 
PIPES   Piperazine-N,N’-bis(2-ethanesulfonic acid) 
PMN   Polymorphonuclear cells  
PNGase F  Peptide -N-Glycosidase F 
PR3   Proteinase 3 
PVDF   Polyvinylidene difluoride 
RCL   Reactive center loop 
RIPA   Radioimmunoprecipitation assay buffer 
ROS   Reactive oxygen species 
rpm   Rounds per minute 
s.c.   Subcutanous 
sec   Seconds 
Ser   Serine 
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Serpin   Serine protease inhibitor 
TACE    Tumor-necrosis-factor-α-converting enzyme 
TCEP    Tris(2-carboxyethyl) phosphine 
TEMED  Tetramethylethylenediamine 
TNFα   Tumor necrosis factor α 
TNFR    Tumor necrosis factor receptor  
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7. Appendix 
7.1 Vector map 
 
 
 
 
Figure 4 Vector map of the pTT5 plasmid. This vector was used to express CysC fusion 
proteins in HEK 293 cells. The important features of this vector are an E. coli (pMB1ori) and 
EBV (OriP) specific origin of replication, a promotor of the cytomegalovirus (CMV), an 
adenovirus tripartite leader (TPL), a major late promotor (MLP), a rabbit bet-globin 
polyadenylation signal (pA) and an ampicillin resistance gene. 
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7.2 Sequences of expressed proteins 
The amino acid sequence is shown in a single letter code. The sequence begins with the Igk 
signal peptide in grey. The C-terminal His-tag is marked in italics and the stop codon is 
represented by a star (*). 
7.2.1 pTT5-Alb 
       1 M  E  T  D  T  L  L  L  W  V  L  L  L  W  V   
       1 ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTA 
      16 P  G  S  T  G  E  A  H  K  S  E  I  A  H  R   
      46 CCAGGTTCCACTGGTGAAGCACACAAGAGTGAGATCGCCCATCGG 
      31 Y  N  D  L  G  E  Q  H  F  K  G  L  V  L  I   
      91 TATAATGATTTGGGAGAACAACATTTCAAAGGCCTAGTCCTGATT 
      46 A  F  S  Q  Y  L  Q  K  C  S  Y  D  E  H  A   
     136 GCCTTTTCCCAGTATCTCCAGAAATGCTCATACGATGAGCATGCC 
      61 K  L  V  Q  E  V  T  D  F  A  K  T  C  V  A   
     181 AAATTAGTGCAGGAAGTAACAGACTTTGCAAAGACGTGTGTTGCC 
      76 D  E  S  A  A  N  C  D  K  S  L  H  T  L  F   
     226 GATGAGTCTGCCGCCAACTGTGACAAATCCCTTCACACTCTTTTT 
      91 G  D  K  L  C  A  I  P  N  L  R  E  N  Y  G   
     271 GGAGATAAGTTGTGTGCCATTCCAAACCTCCGTGAAAACTATGGT 
     106 E  L  A  D  C  C  T  K  Q  E  P  E  R  N  E   
     316 GAACTGGCTGACTGCTGTACAAAACAAGAGCCCGAAAGAAACGAA 
     121 C  F  L  Q  H  K  D  D  N  P  S  L  P  P  F   
     361 TGTTTCCTGCAACACAAAGATGACAACCCCAGCCTGCCACCATTT 
     136 E  R  P  E  A  E  A  M  C  T  S  F  K  E  N   
     406 GAAAGGCCAGAGGCTGAGGCCATGTGCACCTCCTTTAAGGAAAAC 
     151 P  T  T  F  M  G  H  Y  L  H  E  V  A  R  R   
     451 CCAACCACCTTTATGGGACACTATTTGCATGAAGTTGCCAGAAGA 
     166 H  P  Y  F  Y  A  P  E  L  L  Y  Y  A  E  Q   
     496 CATCCTTATTTCTATGCCCCAGAACTTCTTTACTATGCTGAGCAG 
     181 Y  N  E  I  L  T  Q  C  C  A  E  A  D  K  E   
     541 TACAATGAGATTCTGACCCAGTGTTGTGCAGAGGCTGACAAGGAA 
     196 S  C  L  T  P  K  L  D  G  V  K  E  K  A  L   
     586 AGCTGCCTGACCCCGAAGCTTGATGGTGTGAAGGAGAAAGCATTG 
     211 V  S  S  V  R  Q  R  M  K  C  S  S  M  Q  K   
     631 GTCTCATCTGTCCGTCAGAGAATGAAGTGCTCCAGTATGCAGAAG 
     226 F  G  E  R  A  F  K  A  W  A  V  A  R  L  S   
     676 TTTGGAGAGAGAGCTTTTAAAGCATGGGCAGTAGCTCGTCTGAGC 
     241 Q  T  F  P  N  A  D  F  A  E  I  T  K  L  A   
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     721 CAGACATTCCCCAATGCTGACTTTGCAGAAATCACCAAATTGGCA 
     256 T  D  L  T  K  V  N  K  E  C  C  H  G  D  L   
     766 ACAGACCTGACCAAAGTCAACAAGGAGTGCTGCCATGGTGACCTG 
     271 L  E  C  A  D  D  R  A  E  L  A  K  Y  M  C   
     811 CTGGAATGCGCAGATGACAGGGCGGAACTTGCCAAGTACATGTGT 
     286 E  N  Q  A  T  I  S  S  K  L  Q  T  C  C  D   
     856 GAAAACCAGGCGACTATCTCCAGCAAACTGCAGACTTGCTGCGAT 
     301 K  P  L  L  K  K  A  H  C  L  S  E  V  E  H   
     901 AAACCACTGTTGAAGAAAGCCCACTGTCTTAGTGAGGTGGAGCAT 
     316 D  T  M  P  A  D  L  P  A  I  A  A  D  F  V   
     946 GACACCATGCCTGCTGATCTGCCTGCCATTGCTGCTGATTTTGTT 
     331 E  D  Q  E  V  C  K  N  Y  A  E  A  K  D  V   
     991 GAGGACCAGGAAGTGTGCAAGAACTATGCTGAGGCCAAGGATGTC 
     346 F  L  G  T  F  L  Y  E  Y  S  R  R  H  P  D   
    1036 TTCCTGGGCACGTTCTTGTATGAATATTCAAGAAGACACCCTGAT 
     361 Y  S  V  S  L  L  L  R  L  A  K  K  Y  E  A   
    1081 TACTCTGTATCCCTGTTGCTGAGACTTGCTAAGAAATATGAAGCC 
     376 T  L  E  K  C  C  A  E  A  N  P  P  A  C  Y   
    1126 ACTCTGGAAAAGTGCTGCGCTGAAGCCAATCCTCCCGCATGCTAC 
     391 G  T  V  L  A  E  F  Q  P  L  V  E  E  P  K   
    1171 GGCACAGTGCTTGCTGAATTTCAGCCTCTTGTAGAAGAGCCTAAG 
     406 N  L  V  K  T  N  C  D  L  Y  E  K  L  G  E   
    1216 AACTTGGTCAAAACCAACTGTGATCTTTACGAGAAGCTTGGAGAA 
     421 Y  G  F  Q  N  A  I  L  V  R  Y  T  Q  K  A   
    1261 TATGGATTCCAAAATGCCATTCTAGTTCGCTACACCCAGAAAGCA 
     436 P  Q  V  S  T  P  T  L  V  E  A  A  R  N  L   
    1306 CCTCAGGTGTCAACCCCAACTCTCGTGGAGGCTGCAAGAAACCTA 
     451 G  R  V  G  T  K  C  C  T  L  P  E  D  Q  R   
    1351 GGAAGAGTGGGCACCAAGTGTTGTACACTTCCTGAAGATCAGAGA 
     466 L  P  C  V  E  D  Y  L  S  A  I  L  N  R  V   
    1396 CTGCCTTGTGTGGAAGACTATCTGTCTGCAATCCTGAACCGTGTG 
     481 C  L  L  H  E  K  T  P  V  S  E  H  V  T  K   
    1441 TGTCTGCTGCATGAGAAGACCCCAGTGAGTGAGCATGTTACCAAG 
     496 C  C  S  G  S  L  V  E  R  R  P  C  F  S  A   
    1486 TGCTGTAGTGGATCCCTGGTGGAAAGGCGGCCATGCTTCTCTGCT 
     511 L  T  V  D  E  T  Y  V  P  K  E  F  K  A  E   
    1531 CTGACAGTTGATGAAACATATGTCCCCAAAGAGTTTAAAGCTGAG 
     526 T  F  T  F  H  S  D  I  C  T  L  P  E  K  E   
    1576 ACCTTCACCTTCCACTCTGATATCTGCACACTTCCAGAGAAGGAG 
     541 K  Q  I  K  K  Q  T  A  L  A  E  L  V  K  H   
    1621 AAGCAGATTAAGAAACAAACGGCTCTTGCTGAGCTGGTGAAGCAC 
     556 K  P  K  A  T  A  E  Q  L  K  T  V  M  D  D   
    1666 AAGCCCAAGGCTACAGCGGAGCAACTGAAGACTGTCATGGATGAC 
     571 F  A  Q  F  L  D  T  C  C  K  A  A  D  K  D   
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    1711 TTTGCACAGTTCCTGGATACATGTTGCAAGGCTGCTGACAAGGAC 
     586 T  C  F  S  T  E  G  P  N  L  V  T  R  C  K   
    1756 ACCTGCTTCTCGACTGAGGGTCCAAACCTTGTCACTAGATGCAAA 
     601 D  A  L  A  * 
    1801 GAcGCgTTAGCCTGA 
 
7.2.2 pTT5-CysC-Alb 
       1 M  E  T  D  T  L  L  L  W  V  L  L  L  W  V   
       1 ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTA 
      16 P  G  S  T  G  P  R  L  L  G  A  P  E  E  A   
      46 CCTGGCTCAACCGGACCTAGGCTGCTGGGGGCTCCCGAGGAAGCG 
      31 D  A  N  E  E  G  V  R  R  A  L  D  F  A  V   
      91 GATGCTAACGAGGAAGGCGTCAGAAGGGCCTTGGATTTCGCTGTC 
      46 S  E  Y  N  K  G  S  N  D  A  Y  H  S  R  A   
     136 TCAGAGTATAATAAGGGTTCCAACGACGCGTATCATAGCAGGGCA 
      61 C  Q  V  V  R  A  R  K  Q  L  V  A  G  V  N   
     181 TGTCAGGTTGTACGCGCACGGAAACAACTCGTCGCAGGCGTTAAC 
      76 Y  F  L  D  V  E  M  C  R  T  T  C  T  K  S   
     226 TACTTCTTGGATGTGGAAATGTGCCGGACCACGTGCACCAAGAGT 
      91 Q  T  N  L  T  D  C  P  F  H  D  Q  P  H  L   
     271 CAGACCAATCTTACCGACTGCCCATTTCATGACCAACCCCACCTT 
     106 M  R  K  A  L  C  S  F  Q  I  Y  S  V  P  W   
     316 ATGAGAAAGGCCTTGTGCAGTTTCCAGATATATAGCGTACCCTGG 
     121 K  G  T  H  S  L  T  K  F  S  C  K  N  A  G   
     361 AAGGGAACTCATAGCCTGACGAAGTTTAGCTGTAAAAACGCTGGT 
     136 G  G  G  T  G  E  A  H  K  S  E  I  A  H  R   
     406 GGAGGCGGCAccGGTGAAGCACACAAGAGTGAGATCGCCCATCGG 
     151 Y  N  D  L  G  E  Q  H  F  K  G  L  V  L  I   
     451 TATAATGATTTGGGAGAACAACATTTCAAAGGCCTAGTCCTGATT 
     166 A  F  S  Q  Y  L  Q  K  S  S  Y  D  E  H  A   
     496 GCCTTTTCCCAGTATCTCCAGAAAaGCTCATACGATGAGCATGCC 
     181 K  L  V  Q  E  V  T  D  F  A  K  T  C  V  A   
     541 AAATTAGTGCAGGAAGTAACAGACTTTGCAAAGACGTGTGTTGCC 
     196 D  E  S  A  A  N  C  D  K  S  L  H  T  L  F   
     586 GATGAGTCTGCCGCCAACTGTGACAAATCCCTTCACACTCTTTTT 
     211 G  D  K  L  C  A  I  P  N  L  R  E  N  Y  G   
     631 GGAGATAAGTTGTGTGCCATTCCAAACCTCCGTGAAAACTATGGT 
     226 E  L  A  D  C  C  T  K  Q  E  P  E  R  N  E   
     676 GAACTGGCTGACTGCTGTACAAAACAAGAGCCCGAAAGAAACGAA 
     241 C  F  L  Q  H  K  D  D  N  P  S  L  P  P  F   
     721 TGTTTCCTGCAACACAAAGATGACAACCCCAGCCTGCCACCATTT 
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     256 E  R  P  E  A  E  A  M  C  T  S  F  K  E  N   
     766 GAAAGGCCAGAGGCTGAGGCCATGTGCACCTCCTTTAAGGAAAAC 
     271 P  T  T  F  M  G  H  Y  L  H  E  V  A  R  R   
     811 CCAACCACCTTTATGGGACACTATTTGCATGAAGTTGCCAGAAGA 
     286 H  P  Y  F  Y  A  P  E  L  L  Y  Y  A  E  Q   
     856 CATCCTTATTTCTATGCCCCAGAACTTCTTTACTATGCTGAGCAG 
     301 Y  N  E  I  L  T  Q  C  C  A  E  A  D  K  E   
     901 TACAATGAGATTCTGACCCAGTGTTGTGCAGAGGCTGACAAGGAA 
     316 S  C  L  T  P  K  L  D  G  V  K  E  K  A  L   
     946 AGCTGCCTGACCCCGAAGCTTGATGGTGTGAAGGAGAAAGCATTG 
     331 V  S  S  V  R  Q  R  M  K  C  S  S  M  Q  K   
     991 GTCTCATCgGTCCGTCAGAGAATGAAGTGCTCCAGTATGCAGAAG 
     346 F  G  E  R  A  F  K  A  W  A  V  A  R  L  S   
    1036 TTTGGAGAGAGAGCTTTTAAAGCATGGGCAGTAGCTCGTCTGAGC 
     361 Q  T  F  P  N  A  D  F  A  E  I  T  K  L  A   
    1081 CAGACATTCCCCAATGCTGACTTTGCAGAAATCACCAAATTGGCA 
     376 T  D  L  T  K  V  N  K  E  C  C  H  G  D  L   
    1126 ACAGACCTGACCAAAGTCAACAAGGAGTGCTGCCATGGTGACCTG 
     391 L  E  C  A  D  D  R  A  E  L  A  K  Y  M  C   
    1171 CTGGAATGCGCAGATGACAGGGCGGAACTTGCCAAGTACATGTGT 
     406 E  N  Q  A  T  I  S  S  K  L  Q  T  C  C  D   
    1216 GAAAACCAGGCGACTATCTCCAGCAAACTGCAGACTTGCTGCGAT 
     421 K  P  L  L  K  K  A  H  C  L  S  E  V  E  H   
    1261 AAACCACTGTTGAAGAAAGCCCACTGTCTTAGTGAGGTGGAGCAT 
     436 D  T  M  P  A  D  L  P  A  I  A  A  D  F  V   
    1306 GACACCATGCCTGCTGATCTGCCTGCCATTGCTGCTGATTTTGTT 
     451 E  D  Q  E  V  C  K  N  Y  A  E  A  K  D  V   
    1351 GAGGACCAGGAAGTGTGCAAGAACTATGCTGAGGCCAAGGATGTC 
     466 F  L  G  T  F  L  Y  E  Y  S  R  R  H  P  D   
    1396 TTCCTGGGCACGTTCTTGTATGAATATTCAAGAAGACACCCTGAT 
     481 Y  S  V  S  L  L  L  R  L  A  K  K  Y  E  A   
    1441 TACTCTGTATCCCTGTTGCTGAGACTTGCTAAGAAATATGAAGCC 
     496 T  L  E  K  C  C  A  E  A  N  P  P  A  C  Y   
    1486 ACTCTGGAAAAGTGCTGCGCTGAAGCCAATCCTCCCGCATGCTAC 
     511 G  T  V  L  A  E  F  Q  P  L  V  E  E  P  K   
    1531 GGCACAGTGCTTGCTGAATTTCAGCCTCTTGTAGAAGAGCCTAAG 
     526 N  L  V  K  T  N  C  D  L  Y  E  K  L  G  E   
    1576 AACTTGGTCAAAACCAACTGTGATCTTTACGAGAAGCTTGGAGAA 
     541 Y  G  F  Q  N  A  I  L  V  R  Y  T  Q  K  A   
    1621 TATGGATTCCAAAATGCCATTCTAGTTCGCTACACCCAGAAAGCA 
     556 P  Q  V  S  T  P  T  L  V  E  A  A  R  N  L   
    1666 CCTCAGGTGTCAACCCCAACTCTCGTGGAGGCTGCAAGAAACCTA 
     571 G  R  V  G  T  K  C  C  T  L  P  E  D  Q  R   
    1711 GGAAGAGTGGGCACCAAGTGTTGTACACTTCCTGAAGATCAGAGA 
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     586 L  P  C  V  E  D  Y  L  S  A  I  L  N  R  V   
    1756 CTGCCTTGTGTGGAAGACTATCTGTCTGCAATCCTGAACCGTGTG 
     601 C  L  L  H  E  K  T  P  V  S  E  H  V  T  K   
    1801 TGTCTGCTGCATGAGAAGACCCCAGTGAGTGAGCATGTTACCAAG 
     616 C  C  S  G  S  L  V  E  R  R  P  C  F  S  A   
    1846 TGCTGTAGTGGATCCCTGGTGGAAAGGCGGCCATGCTTCTCTGCT 
     631 L  T  V  D  E  T  Y  V  P  K  E  F  K  A  E   
    1891 CTGACAGTTGATGAAACATAcGTaCCCAAAGAGTTTAAAGCTGAG 
     646 T  F  T  F  H  S  D  I  C  T  L  P  E  K  E   
    1936 ACCTTCACCTTCCACTCTGATATCTGCACACTTCCAGAGAAGGAG 
     661 K  Q  I  K  K  Q  T  A  L  A  E  L  V  K  H   
    1981 AAGCAGATTAAGAAACAAACGGCTCTTGCTGAGCTGGTGAAGCAC 
     676 K  P  K  A  T  A  E  Q  L  K  T  V  M  D  D   
    2026 AAGCCCAAGGCTACAGCGGAGCAACTGAAGACTGTCATGGATGAC 
     691 F  A  Q  F  L  D  T  C  C  K  A  A  D  K  D   
    2071 TTTGCACAGTTCCTGGATACATGTTGCAAGGCTGCTGACAAGGAC 
     706 T  C  F  S  T  E  G  P  N  L  V  T  R  C  K   
    2116 ACCTGCTTCTCGACTGAGGGTCCAAACCTTGTCACTAGATGCAAA 
     721 D  A  L  A  T  G  H  H  H  H  H  H  * 
    2161 GAcGCgTTagccaccggtCATCATCACCATCACCATTGA 
 
7.2.3 pTT5-CysC-Alb-Ruby 
       1 M  E  T  D  T  L  L  L  W  V  L  L  L  W  V   
       1 ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTA 
      16 P  G  S  T  G  L  L  G  A  P  E  E  A  D  A   
      46 CCTGGCTCAACCGGACTGCTGGGGGCTCCCGAGGAAGCGGATGCT 
      31 N  E  E  G  V  R  R  A  L  D  F  A  V  S  E   
      91 AACGAGGAAGGCGTCAGAAGGGCCTTGGATTTCGCTGTCTCAGAG 
      46 Y  N  K  G  S  N  D  A  Y  H  S  R  A  C  Q   
     136 TATAATAAGGGTTCCAACGACGCGTATCATAGCAGGGCATGTCAG 
      61 V  V  R  A  R  K  Q  L  V  A  G  V  N  Y  F   
     181 GTTGTACGCGCACGGAAACAACTCGTCGCAGGCGTTAACTACTTC 
      76 L  D  V  E  M  C  R  T  T  C  T  K  S  Q  T   
     226 TTGGATGTGGAAATGTGCCGGACCACGTGCACCAAGAGTCAGACC 
      91 N  L  T  D  C  P  F  H  D  Q  P  H  L  M  R   
     271 AATCTTACCGACTGCCCATTTCATGACCAACCCCACCTTATGAGA 
     106 K  A  L  C  S  F  Q  I  Y  S  V  P  W  K  G   
     316 AAGGCCTTGTGCAGTTTCCAGATATATAGCGTACCCTGGAAGGGA 
     121 T  H  S  L  T  K  F  S  C  K  N  A  G  G  G   
     361 ACTCATAGCCTGACGAAGTTTAGCTGTAAAAACGCTGGTGGAGGC 
     136 G  T  G  E  A  H  K  S  E  I  A  H  R  Y  N   
     406 GGCAccGGTGAAGCACACAAGAGTGAGATCGCCCATCGGTATAAT 
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     151 D  L  G  E  Q  H  F  K  G  L  V  L  I  A  F   
     451 GATTTGGGAGAACAACATTTCAAAGGCCTAGTCCTGATTGCCTTT 
     166 S  Q  Y  L  Q  K  S  S  Y  D  E  H  A  K  L   
     496 TCCCAGTATCTCCAGAAAaGCTCATACGATGAGCATGCCAAATTA 
     181 V  Q  E  V  T  D  F  A  K  T  C  V  A  D  E   
     541 GTGCAGGAAGTAACAGACTTTGCAAAGACGTGTGTTGCCGATGAG 
     196 S  A  A  N  C  D  K  S  L  H  T  L  F  G  D   
     586 TCTGCCGCCAACTGTGACAAATCCCTTCACACTCTTTTTGGAGAT 
     211 K  L  C  A  I  P  N  L  R  E  N  Y  G  E  L   
     631 AAGTTGTGTGCCATTCCAAACCTCCGTGAAAACTATGGTGAACTG 
     226 A  D  C  C  T  K  Q  E  P  E  R  N  E  C  F   
     676 GCTGACTGCTGTACAAAACAAGAGCCCGAAAGAAACGAATGTTTC 
     241 L  Q  H  K  D  D  N  P  S  L  P  P  F  E  R   
     721 CTGCAACACAAAGATGACAACCCCAGCCTGCCACCATTTGAAAGG 
     256 P  E  A  E  A  M  C  T  S  F  K  E  N  P  T   
     766 CCAGAGGCTGAGGCCATGTGCACCTCCTTTAAGGAAAACCCAACC 
     271 T  F  M  G  H  Y  L  H  E  V  A  R  R  H  P   
     811 ACCTTTATGGGACACTATTTGCATGAAGTTGCCAGAAGACATCCT 
     286 Y  F  Y  A  P  E  L  L  Y  Y  A  E  Q  Y  N   
     856 TATTTCTATGCCCCAGAACTTCTTTACTATGCTGAGCAGTACAAT 
     301 E  I  L  T  Q  C  C  A  E  A  D  K  E  S  C   
     901 GAGATTCTGACCCAGTGTTGTGCAGAGGCTGACAAGGAAAGCTGC 
     316 L  T  P  K  L  D  G  V  K  E  K  A  L  V  S   
     946 CTGACCCCGAAGCTTGATGGTGTGAAGGAGAAAGCATTGGTCTCA 
     331 S  V  R  Q  R  M  K  C  S  S  M  Q  K  F  G   
     991 TCTGTCCGTCAGAGAATGAAGTGCTCCAGTATGCAGAAGTTTGGA 
     346 E  R  A  F  K  A  W  A  V  A  R  L  S  Q  T   
    1036 GAGAGAGCTTTTAAAGCATGGGCAGTAGCTCGTCTGAGCCAGACA 
     361 F  P  N  A  D  F  A  E  I  T  K  L  A  T  D   
    1081 TTCCCCAATGCTGACTTTGCAGAAATCACCAAATTGGCAACAGAC 
     376 L  T  K  V  N  K  E  C  C  H  G  D  L  L  E   
    1126 CTGACCAAAGTCAACAAGGAGTGCTGCCATGGTGACCTGCTGGAA 
     391 C  A  D  D  R  A  E  L  A  K  Y  M  C  E  N   
    1171 TGCGCAGATGACAGGGCGGAACTTGCCAAGTACATGTGTGAAAAC 
     406 Q  A  T  I  S  S  K  L  Q  T  C  C  D  K  P   
    1216 CAGGCGACTATCTCCAGCAAACTGCAGACTTGCTGCGATAAACCA 
     421 L  L  K  K  A  H  C  L  S  E  V  E  H  D  T   
    1261 CTGTTGAAGAAAGCCCACTGTCTTAGTGAGGTGGAGCATGACACC 
     436 M  P  A  D  L  P  A  I  A  A  D  F  V  E  D   
    1306 ATGCCTGCTGATCTGCCTGCCATTGCTGCTGATTTTGTTGAGGAC 
     451 Q  E  V  C  K  N  Y  A  E  A  K  D  V  F  L   
    1351 CAGGAAGTGTGCAAGAACTATGCTGAGGCCAAGGATGTCTTCCTG 
     466 G  T  F  L  Y  E  Y  S  R  R  H  P  D  Y  S   
    1396 GGCACGTTCTTGTATGAATATTCAAGAAGACACCCTGATTACTCT 
7. Appendix  
130 
 
     481 V  S  L  L  L  R  L  A  K  K  Y  E  A  T  L   
    1441 GTATCCCTGTTGCTGAGACTTGCTAAGAAATATGAAGCCACTCTG 
     496 E  K  C  C  A  E  A  N  P  P  A  C  Y  G  T   
    1486 GAAAAGTGCTGCGCTGAAGCCAATCCTCCCGCATGCTACGGCACA 
     511 V  L  A  E  F  Q  P  L  V  E  E  P  K  N  L   
    1531 GTGCTTGCTGAATTTCAGCCTCTTGTAGAAGAGCCTAAGAACTTG 
     526 V  K  T  N  C  D  L  Y  E  K  L  G  E  Y  G   
    1576 GTCAAAACCAACTGTGATCTTTACGAGAAGCTTGGAGAATATGGA 
     541 F  Q  N  A  I  L  V  R  Y  T  Q  K  A  P  Q   
    1621 TTCCAAAATGCCATTCTAGTTCGCTACACCCAGAAAGCACCTCAG 
     556 V  S  T  P  T  L  V  E  A  A  R  N  L  G  R   
    1666 GTGTCAACCCCAACTCTCGTGGAGGCTGCAAGAAACCTAGGAAGA 
     571 V  G  T  K  C  C  T  L  P  E  D  Q  R  L  P   
    1711 GTGGGCACCAAGTGTTGTACACTTCCTGAAGATCAGAGACTGCCT 
     586 C  V  E  D  Y  L  S  A  I  L  N  R  V  C  L   
    1756 TGTGTGGAAGACTATCTGTCTGCAATCCTGAACCGTGTGTGTCTG 
     601 L  H  E  K  T  P  V  S  E  H  V  T  K  C  C   
    1801 CTGCATGAGAAGACCCCAGTGAGTGAGCATGTTACCAAGTGCTGT 
     616 S  G  S  L  V  E  R  R  P  C  F  S  A  L  T   
    1846 AGTGGATCCCTGGTGGAAAGGCGGCCATGCTTCTCTGCTCTGACA 
     631 V  D  E  T  Y  V  P  K  E  F  K  A  E  T  F   
    1891 GTTGATGAAACATATGTCCCCAAAGAGTTTAAAGCTGAGACCTTC 
     646 T  F  H  S  D  I  C  T  L  P  E  K  E  K  Q   
    1936 ACCTTCCACTCTGATATCTGCACACTTCCAGAGAAGGAGAAGCAG 
     661 I  K  K  Q  T  A  L  A  E  L  V  K  H  K  P   
    1981 ATTAAGAAACAAACGGCTCTTGCTGAGCTGGTGAAGCACAAGCCC 
     676 K  A  T  A  E  Q  L  K  T  V  M  D  D  F  A   
    2026 AAGGCTACAGCGGAGCAACTGAAGACTGTCATGGATGACTTTGCA 
     691 Q  F  L  D  T  C  C  K  A  A  D  K  D  T  C   
    2071 CAGTTCCTGGATACATGTTGCAAGGCTGCTGACAAGGACACCTGC 
     706 F  S  T  E  G  P  N  L  V  T  R  C  K  D  A   
    2116 TTCTCGACTGAGGGTCCAAACCTTGTCACTAGATGCAAAGAcGCg 
     721 L  A  T  G  S  G  G  G  E  D  N  S  L  I  K   
    2161 TTAGCCACCGGTTCTGGTGGCGGTGAGGATAACAGCCTGATCAAA 
     736 E  N  M  R  M  K  V  V  L  E  G  S  V  N  G   
    2206 GAAAACATGCGGATGAAGGTGGTGCTGGAAGGCAGCGTGAACGGC 
     751 H  Q  F  K  C  T  G  E  G  E  G  N  P  Y  M   
    2251 CACCAGTTCAAGTGCACCGGCGAGGGCGAGGGCAACCCCTACATG 
     766 G  T  Q  T  M  R  I  K  V  I  E  G  G  P  L   
    2296 GGCACCCAGACCATGCGGATCAAAGTGATCGAGGGCGGACCTCTG 
     781 P  F  A  F  D  I  L  A  T  S  F  M  Y  G  S   
    2341 CCCTTCGCCTTCGACATCCTGGCCACATCCTTCATGTACGGCAGC 
     796 R  T  F  I  K  Y  P  K  G  I  P  D  F  F  K   
    2386 CGGACCTTCATCAAGTACCCCAAGGGCATCCCCGATTTCTTCAAG 
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     811 Q  S  F  P  E  G  F  T  W  E  R  V  T  R  Y   
    2431 CAGAGCTTCCCCGAGGGCTTCACCTGGGAGAGAGTGACCAGATAC 
     826 E  D  G  G  V  I  T  V  M  Q  D  T  S  L  E   
    2476 GAGGACGGCGGCGTGATCACCGTGATGCAGGACACCAGCCTGGAA 
     841 D  G  C  L  V  Y  H  A  Q  V  R  G  V  N  F   
    2521 GATGGCTGCCTGGTGTACCATGCCCAGGTCAGGGGCGTGAATTTT 
     856 P  S  N  G  A  V  M  Q  K  K  T  K  G  W  E   
    2566 CCCAGCAACGGCGCCGTGATGCAGAAGAAAACCAAGGGCTGGGAG 
     871 P  N  T  E  M  M  Y  P  A  D  G  G  L  R  G   
    2611 CCCAACACCGAGATGATGTACCCCGCTGACGGCGGACTGAGAGGC 
     886 Y  T  H  M  A  L  K  V  D  G  G  G  H  L  S   
    2656 TACACCCACATGGCCCTGAAGGTGGACGGCGGAGGGCACCTGAGC 
     901 C  S  F  V  T  T  Y  R  S  K  K  T  V  G  N   
    2701 TGCAGCTTCGTGACCACCTACCGATCCAAGAAAACCGTGGGCAAC 
     916 I  K  M  P  G  I  H  A  V  D  H  R  L  E  R   
    2746 ATCAAGATGCCCGGCATCCACGCCGTGGACCACCGGCTGGAAAGG 
     931 L  E  E  S  D  N  E  M  F  V  V  Q  R  E  H   
    2791 CTGGAAGAGTCCGACAACGAGATGTTCGTGGTGCAGCGGGAGCAC 
     946 A  V  A  K  F  A  G  L  P  G  G  H  H  H  H   
    2836 GCCGTGGCCAAGTTCGCCGGCCTGCCTGGAGGGCACCATCACCAT 
     961 H  H  *   
    2881 CACCATTGA 
7.2.4 pTT5-CysC-Ruby 
       1 M  E  T  D  T  L  L  L  W  V  L  L  L  W  V   
       1 ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTA 
      16 P  G  S  T  G  A  T  P  K  Q  G  P  R  M  L   
      46 CCTGGCTCAACCGGAGCTACGCCAAAACAAGGTCCtaGgATGCTG 
      31 G  A  P  E  E  A  D  A  N  E  E  G  V  R  R   
      91 GGGGCTCCCGAGGAAGCGGATGCTAACGAGGAAGGCGTCAGAAGG 
      46 A  L  D  F  A  V  S  E  Y  N  K  G  S  N  D   
     136 GCCTTGGATTTCGCTGTCTCAGAGTATAATAAGGGTTCCAACGAC 
      61 A  Y  H  S  R  A  I  Q  V  V  R  A  R  K  Q   
     181 GCGTATCATAGCAGGGCAATACAGGTTGTACGCGCACGGAAACAA 
      76 L  V  A  G  V  N  Y  F  L  D  V  E  M  G  R   
     226 CTCGTCGCAGGCGTTAACTACTTCTTGGATGTGGAAATGGGACGG 
      91 T  T  C  T  K  S  Q  T  N  L  T  D  C  P  F   
     271 ACcACgTGCACCAAGAGTCAGACCAATCTTACCGACTGCCCATTT 
     106 H  D  Q  P  H  L  M  R  K  A  L  C  S  F  Q   
     316 CATGACCAACCCCACCTTATGAGAAAgGCcTTGTGCAGTTTCCAG 
     121 I  Y  S  V  P  W  K  G  T  H  S  L  T  K  F   
     361 ATATATAGCGTACCCTGGAAGGGAACTCATAGCCTGACGAAGTTT 
     136 S  C  K  N  A  G  G  G  G  T  G  S  G  G  G   
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     406 AGCTGTAAAAACGCTGGTGGAGGCGGCACCGGTTCTGGTGGCGGT 
     151 E  D  N  S  L  I  K  E  N  M  R  M  K  V  V   
     451 GAGGATAACAGCCTGATCAAAGAAAACATGCGGATGAAGGTGGTG 
     166 L  E  G  S  V  N  G  H  Q  F  K  C  T  G  E   
     496 CTGGAAGGCAGCGTGAACGGCCACCAGTTCAAGTGCACCGGCGAG 
     181 G  E  G  N  P  Y  M  G  T  Q  T  M  R  I  K   
     541 GGCGAGGGCAACCCCTACATGGGCACCCAGACCATGCGGATCAAA 
     196 V  I  E  G  G  P  L  P  F  A  F  D  I  L  A   
     586 GTGATCGAGGGCGGACCTCTGCCCTTCGCCTTCGACATCCTGGCC 
     211 T  S  F  M  Y  G  S  R  T  F  I  K  Y  P  K   
     631 ACATCCTTCATGTACGGCAGCCGGACCTTCATCAAGTACCCCAAG 
     226 G  I  P  D  F  F  K  Q  S  F  P  E  G  F  T   
     676 GGCATCCCCGATTTCTTCAAGCAGAGCTTCCCCGAGGGCTTCACC 
     241 W  E  R  V  T  R  Y  E  D  G  G  V  I  T  V   
     721 TGGGAGAGAGTGACCAGATACGAGGACGGCGGCGTGATCACCGTG 
     256 M  Q  D  T  S  L  E  D  G  C  L  V  Y  H  A   
     766 ATGCAGGACACCAGCCTGGAAGATGGCTGCCTGGTGTACCATGCC 
     271 Q  V  R  G  V  N  F  P  S  N  G  A  V  M  Q   
     811 CAGGTCAGGGGCGTGAATTTTCCCAGCAACGGCGCCGTGATGCAG 
     286 K  K  T  K  G  W  E  P  N  T  E  M  M  Y  P   
     856 AAGAAAACCAAGGGCTGGGAGCCCAACACCGAGATGATGTACCCC 
     301 A  D  G  G  L  R  G  Y  T  H  M  A  L  K  V   
     901 GCTGACGGCGGACTGAGAGGCTACACCCACATGGCCCTGAAGGTG 
     316 D  G  G  G  H  L  S  C  S  F  V  T  T  Y  R   
     946 GACGGCGGAGGGCACCTGAGCTGCAGCTTCGTGACCACCTACCGA 
     331 S  K  K  T  V  G  N  I  K  M  P  G  I  H  A   
     991 TCCAAGAAAACCGTGGGCAACATCAAGATGCCCGGCATCCACGCC 
     346 V  D  H  R  L  E  R  L  E  E  S  D  N  E  M   
    1036 GTGGACCACCGGCTGGAAAGGCTGGAAGAGTCCGACAACGAGATG 
     361 F  V  V  Q  R  E  H  A  V  A  K  F  A  G  L   
    1081 TTCGTGGTGCAGCGGGAGCACGCCGTGGCCAAGTTCGCCGGCCTG 
     376 P  G  G  H  H  H  H  H  H  *   
    1126 cctggagggCACCATCACCATCACCATTGA 
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